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Abstract 
Cancer is a group of diseases that are characterized by uncontrolled growth and spread of 
cells. In order to treat cancer successfully, it is important to diagnose cancers in their early stages, 
because survival often depends on the stage of cancer detection. For that purpose, highly sensitive 
and selective methods must be developed, taking advantage of suitable biomarkers. The expression 
levels of proteases differ from one cancer type to the other, because different cancers arise from 
different cell types. According to the literature, there are significant differences between the 
protease expression levels of cancer patients and healthy people, because solid tumors rely on 
proteases for survival, angiogenesis and metastasis.  
Development of fluorescence-based nanobiosensors for the early detection of pancreatic 
cancer and non-small-cell lung cancer is discussed in this thesis. The nanobiosensors are capable 
of detecting protease/arginase activities in serum samples over a broad range. The functionality of 
the nanobiosensor is based on Förster resonance energy transfer and surface energy transfer 
mechanisms.  
The nanobiosensors for protease detection feature dopamine-coated Fe/Fe3O4 
nanoparticles, consensus (cleavage) peptide sequences, meso-tetra(4-carboxyphenyl)porphine 
(TCPP), and cyanine 5.5. The consensus peptide sequences were synthesized by solid-supported 
peptide synthesis. In this thesis, improved consensus sequences were used, which permit faster 
synthesis and higher signal intensities. TCPP, which is the fluorophore of the nanoplatform, was 
connected to the N-terminal end of the oligopeptides while it was still on the resin. After the 
addition of TCPP, the TCPP-oligopeptide was cleaved off the resin and linked to the primary amine 
groups of Fe/Fe3O4-bound via a stable amide bond.  
  
In the presence of a particular protease, the consensus sequences attached to the 
nanoparticle can be cleaved and release TCPP to the aqueous medium. Upon releasing the dye, the 
emission intensity increases significantly and can be detected by fluorescence spectroscopy or, 
similarly, by using a fluorescence plate reader. In sensing of arginase, posttranslational 
modification of the peptide sequence will occur, transforming arginine to ornithine. This changes 
the conformational dynamics of the oligopeptide tether, leading to the increase of the TCPP signal. 
This is a highly selective technology, which has a very low limit of detection (LOD) of 1 x 10-16 
molL-1 for proteases and arginase. 
The potential of this nanobiosensor technology to detect early pancreatic and lung cancer 
was demonstrated by using serum samples, which were collected from patients who have been 
diagnosed with pancreatic cancer and non-small cell lung cancer at the South Eastern Nebraska 
Cancer Center (lung cancer) and the University of Kansas Cancer Center (pancreatic cancer).  As 
controls, serum samples collected from healthy volunteers were analyzed. 
In pancreatic cancer detection, the protease/arginase signature for the detection of 
pancreatic adenocarcinomas in serum was identified. It comprises arginase, MMPs -1, - 3, and -9, 
cathepsins -B and -E, urokinase plasminogen activator, and neutrophil elastase. 
For lung cancer detection, the specificity and sensitivity of the nanobiosensors permit the 
accurate measurements of the activities of nine signature proteases in serum samples. Cathepsin   
-L and MMPs-1, -3, and -7 permit detecting non-small-cell lung-cancer at stage 1. 
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Abstract 
Cancer is a group of diseases that are characterized by uncontrolled growth and spread of 
cells. In order to treat cancer successfully, it is important to diagnose cancers in their early stages, 
because survival often depends on the stage of cancer detection. For that purpose, highly sensitive 
and selective methods must be developed, taking advantage of suitable biomarkers. The expression 
levels of proteases differ from one cancer type to the other, because different cancers arise from 
different cell types. According to the literature, there are significant differences between the 
protease expression levels of cancer patients and healthy people, because solid tumors rely on 
proteases for survival, angiogenesis and metastasis.  
Development of fluorescence-based nanobiosensors for the early detection of pancreatic 
cancer and non-small-cell lung cancer is discussed in this thesis. The nanobiosensors are capable 
of detecting protease/arginase activities in serum samples over a broad range. The functionality of 
the nanobiosensor is based on Förster resonance energy transfer and surface energy transfer 
mechanisms.  
The nanobiosensors for protease detection feature dopamine-coated Fe/Fe3O4 
nanoparticles, consensus (cleavage) peptide sequences, meso-tetra(4-carboxyphenyl)porphine 
(TCPP), and cyanine 5.5. The consensus peptide sequences were synthesized by solid-supported 
peptide synthesis. In this thesis, improved consensus sequences were used, which permit faster 
synthesis and higher signal intensities. TCPP, which is the fluorophore of the nanoplatform, was 
connected to the N-terminal end of the oligopeptides while it was still on the resin. After the 
addition of TCPP, the TCPP-oligopeptide was cleaved off the resin and linked to the primary amine 
groups of Fe/Fe3O4-bound via a stable amide bond.  
  
In the presence of a particular protease, the consensus sequences attached to the 
nanoparticle can be cleaved and release TCPP to the aqueous medium. Upon releasing the dye, the 
emission intensity increases significantly and can be detected by fluorescence spectroscopy or, 
similarly, by using a fluorescence plate reader. In sensing of arginase, posttranslational 
modification of the peptide sequence will occur, transforming arginine to ornithine. This changes 
the conformational dynamics of the oligopeptide tether, leading to the increase of the TCPP signal. 
This is a highly selective technology, which has a very low limit of detection (LOD) of 1 x 10-16 
molL-1 for proteases and arginase. 
The potential of this nanobiosensor technology to detect early pancreatic and lung cancer 
was demonstrated by using serum samples, which were collected from patients who have been 
diagnosed with pancreatic cancer and non-small cell lung cancer at the South Eastern Nebraska 
Cancer Center (lung cancer) and the University of Kansas Cancer Center (pancreatic cancer).  As 
controls, serum samples collected from healthy volunteers were analyzed. 
In pancreatic cancer detection, the protease/arginase signature for the detection of 
pancreatic adenocarcinomas in serum was identified. It comprises arginase, MMPs -1, - 3, and -9, 
cathepsins -B and -E, urokinase plasminogen activator, and neutrophil elastase. 
For lung cancer detection, the specificity and sensitivity of the nanobiosensors permit the 
accurate measurements of the activities of nine signature proteases in serum samples. Cathepsin   
-L and MMPs-1, -3, and -7 permit detecting non-small-cell lung-cancer at stage 1.
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Chapter 1 - Biochemical Foundations of Diagnosing Solid Tumors in 
Lung and Pancreas by Means of Liquid Biopsies 
 1.1 Introduction 
Cancer is a group of diseases that are characterized by an uncontrolled growth and spread 
of cells. Cancer can develop anywhere in the human body, and produce large number of cells. In 
a healthy human body, cells normally grow up and divide in order to make new cells according to 
the body’s needs. If these cells are damaged or aged, they die and new cells replace them. This 
process runs as a cycle. When a cancer starts to develop, cells become more and more abnormal. 
With the development of cancer, new cells develop even if they are not required and old cells, 
which are supposed to die, survive their damages and become virtually immortal. The unstoppable 
division of cells form cell growths called tumors. There are different types of tumors. Many of 
them form solid tumors, which contain solid masses of tissue.1  
Cancer can develop due to external factors, as well as internal factors. Cancers occur due 
to external factors, such as the usage of tobacco, infectious organisms, as well as exposure to 
chemicals and radiation, are avoidable. But the development of a cancer due to internal factors, 
such as inherited mutations, hormones, immune conditions, and mutations that occur due to 
changes in the metabolism, are unavoidable. These factors can act together or individually to 
initiate a cancer in a human body. 
Cancers can be categorized into different stages. The “stage of cancer” is the stage where 
the cancer was at when it was first diagnosed. In stage 0, cancer is in the position where it started. 
Some cancers never go beyond this early stage. At stage 1, which is called localized cancer, cells 
gain the ability to pass through the “basement membrane” but remain as a single lump. Cancer 
stays partly in the tissue where it began and partly in a neighboring tissue. In stages 2 and 3, cancer 
2 
cells can invade lymph nodes and then divide, forming a lump in the lymph node. This is called 
“regional spread”. There, the cancer has spread within the general region in which it first began 
but not to other parts of the body. Stage 4 is referred to as the “distant spread”. In this stage, cells 
invade the blood stream, and then can go anywhere in the body to form new colonies and spread 
further. Identifying the stage of the cancer is very important because it is a critical factor in 
deciding the best way to treat the cancer.2 
There are more than 100 types of cancer. Cancers are usually named based on the organs 
or tissues where the cancers form. There are several ways to treat cancer, such as surgery, radiation, 
chemotherapy, hormone therapy, biological therapy, and targeted therapy.3 Regular screening 
examinations can help detecting cancer at its early stages, as well as removal of precancerous 
growths. Cancers developing in cervix, colon, and rectum can be prevented by removal of 
precancerous tissue. Cancers that can be diagnosed early via screening include cancers of the 
breast, colon, rectum, cervix, prostate, oral cavity, and skin.3 
Eventhough anyone can develop cancer, the risk of being diagnosed with a cancer increases 
with age. According to the statistics, about 77% of all cancers are diagnosed in persons 55 years 
of age and older.3 According to the statistics, the probability of developing a particular type of 
cancer and the mortality depends on the gender as well. 
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Figure 1: 2016 Estimated US Cancer Cases (Taken with permission of Reference 4) 
 
 1.2 Early cancer detection 
In order to treat cancer successfully, it is important to diagnose cancer in early stages. 
Therefore, it is required to have highly sensitive methods to measure cancer diagnosis markers. 
Early diagnosis of cancer leads to better treatment methods and thereby reduce the mortality rate 
by increasing the survival rate.  
Most of the cancer related diagnostics have been studied using enzyme-linked 
immunosorbent assay (ELISA). ELISA is a common laboratory technique which is used to 
measure the concentration of an analyte (usually antibodies or antigens) in a solution.  In 
cancer diagnostics, ELISA is used to measure the protease/protein concentrations in biological 
samples.5 But it is hard to determine the activity of different types of proteases which are associated 
with cancer by using ELISA. Proteases usually occur as inactive precursors (zymogens), active 
enzymes or enzyme inhibitor complexes which makes difficult in measuring activity to analyze 
stages of the cancer.  
Apart from ELISA, there are different methods use to diagnose cancer. Electrochemical 
biosensors6, immunohistochemical methods7, chemiluminescence immunosensors8 and 
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fluorescence in situ hybridization9 are few of those widely used methods. Eventhough these 
methods have been used widely to detect cancer, early detection of cancer has become a challenge 
due to the lack of sensitivity of the techniques. It is required to have highly sensitive techniques to 
detect very low molar concentrations of cancer related biomarkers.  
 The research I have included in my thesis are based on a development of fluorescence 
based nanobiosensors10 for the early detection of pancreatic cancer and lung cancer. This is a 
previously established method and has been used for early detection of breast cancer.11 In my 
research, the similar technique is used to detect pancreatic and lung cancer in their early stages. 
The functionality of the nanobiosensors are based on the Förster resonance energy transfer 
mechanism. 
 
 1.3 Förster resonance energy transfer (FRET) 
FRET is defined as radiationless energy transfer from an energetically excited fluorophore 
(donor) to another molecule (acceptor) through dipole-dipole coupling through space. After FRET 
has completed, the excited acceptor molecule loses its energy via photon emission or internal 
conversion and returns back to the ground state.12 
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Figure 2: Schematic representation of FRET demonstrating the energy transfer from 
excited donor (D*) to acceptor (A) via nonradiative process. Note that external conversion 
of the acceptor is not shown (Taken with permission of Reference 12) 
 
FRET efficiency (EFRET) varies with the sixth power of the distance between the two 
molecules and can be expressed by the following equation.12 
 
R0 is the Förster radius or critical distance, which is the characteristic distance at a FRET 
efficiency of 50%. This FRET efficiency is varying for different FRET pairs. FRET efficiency is 
close to maximum at distances less than R0, and minimum for distances greater than R0. In an 
aqueous solution, R0 is determined by following equation.
12 
R 0 =[8.79×10
− 5 (κ2 η−4QDJ (λ))] 1 / 6      Å  
κ2 is the angle between the two fluorophore dipole moments, QD is the donor quantum yield 
and η is the refractive index of the medium. J(λ) is the spectral overlap integral between the 
normalized donor fluorescence, FD(λ), and the acceptor absorption spectra (which is a direct 
measure of the molar extinction coefficient, ɛA(λ)).12 
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J(λ) is determined by the following equation: 
 
 
Figure 3: Graphical representation of spectral overlapping, J(λ), between donor 
fluorescence/emission spectra and acceptor absorption spectra (Taken with permission of 
Reference12) 
 
 
Figure 4: Energy transfer efficiency E as a function of the distance between donor and 
acceptor (nm), and the Förster radius R0 
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 1.4 Designs of the Nanobiosensors 
These nanobiosensors were developed for the early detection of pancreatic cancer and non-
small cell lung cancer. For the early detection of pancreatic cancer, Fe/Fe3O4-based 
nanobiosensors for protease10,11 and arginase13 were developed and patented in the 
Bossmann/Troyer groups were used. This technology facilitates the detection of enzymetic 
activities by measuring the fluorescence increase of a nanoparticle-linked fluorophore upon 
cleavage or posttranslational modification of an oligopeptide sequence. The synthesis of the 
nanobiosensors were done according to an established and published procedures.  
Nanobiosensors synthesized for proteases contain dopamine coated Fe/Fe3O4 
nanoparticles, TCPP, and cyanine 5.5. Water dispersible, dopamine coated Fe/Fe3O4 nanoparticles, 
TCPP, and cyanine 5.5 were synthesized according to established procedures.11 The consensus 
peptide sequences were synthesized by solid-supported peptide synthesis.11 TCPP which is the 
fluorophore of the nanoplatform was connected to the N-terminal end of the oligopeptides while 
it is still on the resin.  
After the addition of TCPP, the TCPP-oligopeptide is cleaved off the resin and linked to 
the primary amine groups of Fe/Fe3O4-bound via an amide bond.
11 Each consensus peptide 
sequence contains GAG and AG as peptide spacers at the N- and C-terminal ends of the 
oligopeptide. This facilitates the access by the enzymes to their respective consensus sequence.  
The average core diameter of Fe (0) is 13 +/- 0.5 nm and Fe3O4 shell thickness of 2.0 ± 0.5 
nm, respectively. Following a random-deposition, cyanine 5.5 is directly bound to the dopamine 
coated nanoparticle and the determined optimal density is 50+/-4 per nanoparticle. TCPP is 
attached to the nanoparticle via oligopeptide and the density is 35+/-3 per nanoparticle. The 
distribution of ligands per nanoparticle follows a Poisson distribution. Unreacted low molecular 
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weight components, dyes and oligopeptides will be removed from the nanoplatform via dialysis. 
Nanoplatform undergoes lyophilisation and dried completely prior to use. 
 
 
 
Figure 5: A: Function principle of nanobiosensors for protease detection: the consensus 
sequence is cut by the protease; B: Function principle of nanobiosensors for posttranslational 
modification: the chemical identity of amino acids in the linker is changed via enzymatic 
reaction; C: Typical emission spectra occurring from the nanosensor for MMP-3 after 1h of 
incubation at 37oC (λexc = 421nm). a: buffer; b: nanosensor; c: nanobiosensor after 
incubation with MMP-3 
 
 1.5 Proteases 
Proteases are a class of enzymes which involve with cleaving peptide bonds in specific 
peptide chain in a particular protein. There are different types of catalytic classes of proteases such 
as aspartic, metallo-, cysteine, serine, threonine and glutamic. Depending on the group involving 
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in nucleophilic attack at the carbonyl group, the proteases have been categorized. Aspartic, 
metallo- and glutamic proteases have a polarized water molecule as the nucleophile at the active 
center while serine and threonine proteases have the hydroxyl group and cysteine proteases have 
the sulfhydryl group at the active center. 
There are few proteases which are necessary for cancer development and progression. 
Those are Matrix Metallo-proteinases (MMPs), urokinase plasminogen activator (uPA) and 
Cathepsins (CTSs).14 These proteases are expressed during the tumor progression and metastasis.15 
These proteases incorporate with each other and act in cascade like manner. The cancer related 
proteases are important and possess reliability as specific biomarkers for the early cancer detection.  
Extracellular proteases play a major role in  transforming pancreatic cancer into metastatic 
and invasive phenotype.16 The expression and the activity of proteases will vary depending on the 
cell type that express the protease. It has been found that in many cancer types, proteases are 
produced by the stromal and inflammatory cells.17 For an example, in pancreatic cancer, there are 
cancer cells which will induce urokinase (uPA) in stromal cells but will bind to the urokinase 
receptors on cancer cells.18 
Three main proteases which are related to cancer are discussed below. 
 
 1.5.1 Matrix Metalloproteinases 
Matrix metalloproteinases (MMPs) is a family of enzymes which has been identified as a 
major player in tumor progression.19 MMPs are involved in degradation of the extracellular matrix 
while wound healing, bone resorption, being a part of pathological conditions such as rheumatoid 
arthritis, coronary artery disease and cancer.19 It has been identified that the cancer cells (tumor 
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cells) use the ability of MMPs to degrade matrix and spread to the sites far away from the tumor 
environment. MMPs are believed to promote the growth of tumor cells.  
There are five subdivisions of MMP family; the collagenases, the stromelysins, the 
gelatinases, PUMP-1 or matrilysin and membrane type (MT) MMPs.19 The common 
characteristics of these metal containing proteases are degrading at least one basement membrane 
component, active at physiological pH, requires two Zn2+ ions to be active, inhibited by metal 
chelators and tissue inhibitors of metalloproteinases and secreted as zymogens while require 
activation extracellularly.20,21 All MMPs have at least three domains; a hydrophobic pre-peptide 
domain, an amino terminal propeptide domain and a Zn2+ catalytic domain.20,21 There are three 
levels in MMPs regulations; alteration of gene expression, activation of latent zymogens and 
inhibition by tissue inhibitors of metalloproteinases. It has been found that the changes in these 
three levels are associated with tumor progression.22 Once MMPs are activated, they can be 
activated by themselves as well. MMP-3 activates MMP-2 while MMP-9 activates MMP-7.19 
Metastasis is a hallmark of cancer. In metastasis, the cells from primary tumor get 
colonized in distant sites of the body. There are several major steps involved in metastasis such as 
tumor cells break from the primary tumor, invasion of cancer cells through the basal membrane 
into a blood or lymphatic vessel, survival of tumor cells, extravasation from blood or lymphatic 
circulation and colonization of tumor cells and angiogenesis to form metastatic lesion.23 
Angiogenesis is required for the metastases to grow and includes few steps; the release of 
angiogenic factors, release of proteolytic enzymes to degrade postcapillary venule basement 
membrane, endothelial cell migration to the tumor, endothelial cell proliferation and microvessel 
formation and differentiation.24 
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In order to invade extracellular matrix, malignant cells require proteases. Proteases are used 
by metastatic cells to invade through the basement membrane and underlying connective tissues, 
basement membrane of small blood vessels and lynphatics.19 MMPs play a major role in tumor 
angiogenesis. According to many studies, endothelial cells can express and activate MMPs and 
TIMPs differentially. MMP-1 is a main protease in angiogenic cascade. 
 
Table 1: Matrix Metalloproteinases (Reproduced with permission of Reference 25) 
Protease  Common/other names 
MMP-1 Collagenase-1 / fibroblast collagenase 
MMP-2 Gelatinase-A / 72kDa gelatinase 
MMP-3 Stomelysin-1 / transin-1 
MMP-7 Matrilysin / PUMP 
MMP-8 Collagenase-2 / neutrophil collagenase 
MMP-9 Gelatinase-B / 92 kDa gelatinase 
MMP-10 Stromelysin-2 / transin-2 
MMP-11 Stromelysin-3 
MMP-12 Macrophage metalloelastase 
MMP-13 Collagenase-3 / rat collagenase 
MMP-14 MT1-MMP (membrane-type MMP) 
MMP-15 MT2-MMP 
MMP-16 MT3-MMP 
MMP-17 MT4-MMP 
MMP-18 Collagenase-4 
MMP-19 - 
MMP-20 Enamelysin 
MMP-21 - 
MMP-22 - 
MMP-23 CA-MMP 
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MMP-24 MT5-MMP 
MMP-25 Leukolysin / MT6-MMP 
MMP-26 Endometase / matrilysin-2 
 
 
Table 2: Key matrix metalloproteinases in relation with the stages of cancer progression 
and their effect (Reproduced with permission of Reference 26) 
MMP Effect 
Cancer cell invasion  
Several MMPs (MT1-MMP, MMP-2 and 
MMP-9) 
Degrade physical barriers 
Cancer cell proliferation  
MMP-1, -2, -3, -7, -9, -11, -19 Proliferation 
MMP-3, -7, ADAM17, ADAM10 Proliferation 
MMP-9, -2, -14 Proliferation 
Cancer cell apoptosis  
MMP-7, ADAM10 Anti-apoptotic 
Tumor angiogenesis and vasculogenesis  
Several MMPs (MMP-2, -9 MMP-3, -10, -11 
MMP-1, -8, -13) 
Angiogenesis up-regulation/down-regulation 
Cell adhesion, migration, and epithelial to 
mesenchymal transition 
 
MMP-2 Promote migration 
MMP-2, -3, -9, -13, -14 
Induction of EMT (Epithelial-to-mesenchymal 
transition); cell migration 
Immune surveillance  
MMP-9 Decrease T-lymphocyte proliferation 
MMP-9, -2, -14 
Decrease T-lymphocyte reaction against 
cancer cells 
MMP-7, -11, -1, -8, -3 
Decrease cancer cell sensitivity to natural 
killer cells 
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 1.5.2 Cathepsins 
Cathepsins are globular proteases which have intracellular and extracellular functions. In 
cathepsin family, there are 14 types of cathepsins, cathepsin A, B, C, D, E, F, G, H, L, K, O, S, V 
and W.27 In humans, cysteine cathepsin family comprises 11 members. The largest class of 
cathepsin is represented by cathepsin B, C, F, H, L, K, O, S, V, W and X which are cysteine 
proteases of the papain family.28 Initially cathepsins are synthesized as inactive proenzymes. Then 
they are processed to become mature and active enzymes.  
 
Figure 6: Cysteine cathepsins expressed in tumor cells and tumor-associated cells which 
contribute to neoplastic progression (Taken with permission of Reference 29) 
 
Cystein cathepsins are involved in apoptosis, angiogenesis, cell proliferation and invasion. 
Protein degradation and processing are the main functions of cysteine cathepsins in normal cells.30 
Studies have found that the activity levels and expression of some cysteine cathepsins are 
upregulated in human as well as mouse cancers. 
14 
 
Figure 7: Cystein Cathepsins (Taken with permission of Reference 31) 
 
Figure 8 shows the cysteine cathepsin expression of tumor and tumor associated cells in 
caner progression.  
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Cysteine cathepsins expressed in tumor cells and tumor-associated cells which 
contribute to neoplastic progression (Taken with permission of Reference 29) 
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1.5.3 Serine Proteases 
 Serine proteases have a close relationship with cell growth and differentiation. Urokinase 
is one of the serine proteases which is closely associated with tumor invasion and metastasis.31 It 
has been found that the expression and enzyme activity regulation of serine proteases are related 
to the malignant phenotypes of tumors. Matriptase and trypsin are two other serine proteases 
involved in cancer.32 Matriptase is responsible for angiogenesis, extracellular matrix degradation 
and epithelial cancer progression.33 In normal cells, matriptase is inhibited by hepatocyte growth 
factor activator inhibitor-1(HAI-1). The expression of matriptase and loss of HAI-1 can be seen in 
prostate cancer progression.  According to the studies, the ratio between matriptase and HAI-1 act 
as a very good biomarker for prostate cancer progression.34  
Trypsin is a well characterized protease among other serine proteases. Trypsin is associated 
with food digestion, blood coagulation, fibrinolysis, and control of blood pressure. Apart from 
those, trypsin plays a major role in atherosclerosis, inflammation and cancer.32 Trypsin is secreted 
in pancreatic juice as an inactive zymogen (trypsinogen) and activated by enteropeptidase to 
trypsin.35 This was done for physiological protection against premature activity. Antiprotease 
mediator pancreatic secretory trypsin inhibitor (PSTI) also protects from premature activity, but 
the imbalance between protease and antiprotease system leads to the development of pancreatitis. 
This makes a risk to develop pancreatic adenocarcinoma.32 Trypsin also associated with colorectal 
carcinogenesis while promoting cell proliferation, invasion and metastasis.36 
Urokinase plasminogen activator (uPA) is also a serine protease which plays a major role 
in cancer development. It is associated with extracellular matrix degradation as well as basement 
membrane dissolution.37 
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Table 3: Serine protease expression in cancer (Taken with permission of Reference38) 
  
 
 1.6 Pancreatic Cancer 
Pancreatic cancer is one of the deadliest diseases among other various types of cancer.39 In 
United States, pancreatic adenocarcinoma is the third leading cause of cancer deaths for both male 
and female.  Since 2003, the death rates due to other cancer types (lung, colorectal, breast, and 
prostate) were declined while pancreatic adenocarcinoma has increased.3 
It has been recorded that, since 1998, incidence rates for pancreatic cancer is increasing by 
0.8% per year in men and by 1.0% per year in women.3 The calculated death rate for pancreatic 
cancer has been increased from 2003 to 2007 by 0.7% and 0.1% for men and women respectively.3 
 
 1.6.1 Early signs and symptoms 
It is difficult to identify the early symptoms of pancreatic cancer. Most of the time 
pancreatic cancers develop without initial stage symptoms. It has been found out that only a small 
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number of pancreatic cancer patients have showed the early symptoms of the disease. But 
researchers were unable to find out a specific pattern of early symptoms for the early diagnosis. 
The signs and symptoms associated with pancreatic cancer are; pain in upper abdomen which can 
spread over the back, weight loss, loss of appetite, high blood glucose, dark urine, yellow skin and 
eyes etc.3 According to the studies, 4% of the pancreatic diagnosed patients had sudden disgust for 
preferred tastes such as coffee, smoking, wine etc. for more than 6 months prior to the disease 
diagnosis.40 Also 5% of the patients had weakness, loss of appetite while 1% of patients had attacks 
of acute pancreatitis.4 Due to the vagueness of these early symptoms, it is difficult to use these 
situations in diagnosis of pancreatic cancer in its early stages. 
 
 1.6.2 Risk factors 
The incident rates of pancreatic cancer are twice higher in smokers than nonsmokers. It has 
been found that 25%-30% of pancreatic cancer cases were caused by smoking cigarette.41 This 
indicates that the risk for pancreatic cancer is increased by tobacco smoking and use of smokeless 
tobacco. Family history of pancreatic cancer and the personal history of pancreatitis increase the 
risk for pancreatic cancer. Apart from that, alcohol consumption, diabetes, obesity and 
consumption of red meat are some of the risk factors associated with pancreatic cancer.3 
 
 1.6.3 Diagnosis 
In pancreatic cancer, the symptoms are undetectable until it spreads over to distant organs. 
That causes the early detection of pancreatic cancer more difficult and challenging. Currently, 
there is no specific diagnostic method to detect pancreatic cancer in its early stages. Only 8% of 
18 
pancreatic cancer cases have been detected at early stages and there are ongoing research 
developments for early detection of pancreatic cancer.3 
 
 1.6.4 Treatments 
There are several different options available for the treatment of pancreatic cancer. 
Surgery, radiation therapy and chemotherapy options help to increase the survival rate of patients 
and relieve symptoms. But those methods will not produce cure very often. Most of the time 
pancreatic cancer is detected after it spreads beyond the pancreas. Therefore, less than 20% of 
patients undergo surgery for the removal of the cancer.3 Gemcitabine is a chemotherapy drug used 
to treat the patients who undergo surgeries. This increases the survival of many patients after going 
through a surgery. Erlotinib (Tarceva) is another anticancer drug used along with gemcitabine for 
the improvement of pancreatic cancer survival.3 
 
 1.6.5 Survival and deaths 
According to the literature, with all combines stages, 1 and 5 year relative survival rates 
are 26% and 6% respectively. It has been found that the 5 year survival for pancreatic cancer is 
very less regardless of stage. During 2001-2007, five-year survival rate for local-staged cancer, 
regional-staged cancer, and distant-staged cancer are 21.9%, 9.1% and 1.8% respectively. 
According to the estimated calculations, 37390 deaths were expected to occur in 2012 in both men 
and women populations.3 
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Figure 9: Pancreatic cancer 5-year relative survival and 95% confidence intervals (Taken 
with permission of Reference 42) 
 
 1.6.6 Pancreatic cancer and Proteases 
As discussed earlier, pancreatic cancer is a challenging disease which has 5 years survival 
rate less than 6%.43 Therefore, in developed countries, disregarding the advanced medical therapies 
and surgical techniques available, pancreatic cancer lead to the higher number of deaths compared 
to the other cancer related deaths.44 Early dissemination and high local tumor progression are the 
major hallmarks associated with pancreatic cancer. Due to those factors, ¾ patients diagnosed with 
this disease will not undergo initial treatments thus leading to a high mortality rate among 
pancreatic cancer patients.43 Generally, in cancer, invasion and metastasis taking place at the tumor 
environment. In tumor environment, tumor cells and stroma can exchange signals in order to 
increase cell proliferation, cell migration as well as survival.43 
20 
Several types of proteases play a significant role in the progression and development of 
pancreatic cancer. According to the previous studies, MMP-2, MMP-9, TIMP-1 and TIMP-2 were 
found in excess amounts in pancreatic cancer tissue samples with compared to the normal 
pancreatic tissue samples.45 While collagens type I and III are localized in spindle shaped stromal 
cells, MMP-9 was elevated in the tumor cells. MMP-2 elevated amounts also found in stromal 
cells. More MMP-2, MMP-9, TIMP-1 and TIMP-2 were detected in both tumor cells and stromal 
cells. Even distribution of TIMP-1 and TIMP-2 were seen in tumor and stromal cells.45 This study 
shows a good correlation between MMPs and TIMPs overexpression with collagen protein levels 
and transcript coding levels for ECM proteins. 
In chronic pancreatitis, elevated levels of MMP-2 and TIMP-2 were recorded. But mRNA 
encoding transcripts for MMP-1, MMP-3 and TIMP-1 were not detected in chronic pancreatitis 
tissues.46 Immunohistochemistry has proven that the MMP-2, MMP-3 and TIMP-1 levels are 
higher in pancreatic and ampullary carcinomas. The studies show that the immunoreactivity in 
pancreatic and ampullary malignant epithelial cells is greater than in stromal tissues.47 
Type IV collagen distribution in basement membrane tissues in pancreatic adenocarcinoma 
was found to be discontinuous and irregular. This may be due to the abnormal degradation and 
deposition of collagen.48 In pancreatic ductal adenocarcinoma, tumor extracts show the elevated 
amounts of collagen I and V.49 
 
 1.7 Lung Cancer 
Lung cancer is the most common cancer worldwide.  In 2012, we had 1.8 million new cases 
and caused 1.6 million deaths.50 It is a leading cancer killer of men and women in the United States 
and since 1987, lung cancer mortality has surpassed breast cancer mortality among women.51 In 
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2016, it has been estimated that 158,080 Americans died from lung cancers. This is approximately 
27% all recorded cancer deaths.4 The lung cancer mortality patterns show differences between 
men and women, depending whether they are smokers or not.   
Lung cancer is predominantly detected in the elderly. The majority of lung cancer patients 
are diagnosed within the last 5 years of disease progression. According to the statistics, in 2013, 
83% of lung cancer patients were 60 years of age or older.52  
 
 1.7.1 Early signs and symptoms 
Most lung cancers do not show any symptoms or signs until they become distant. There 
are common symptoms of lung cancer, such as a cough that does not go away, blood or rust-
colored sputum that is coughed-up, chest pain, hoarseness, loss of appetite and weight loss, feeling 
tired, as well as the occurrence of lung infections and pneumonia.3 If lung cancer spreads to distant 
organs, bone pain, headache, dizziness, seizures, yellow skin and eyes and lumps near the surface 
of the body may occur.3 
 
 1.7.2 Risk factors 
The main risk factor for lung cancer is cigarette smoking. Studies show that the cigar and 
pipe smoking also can increase the risk of getting a lung cancer.3 The risk of getting a lung cancer 
increases with the quantity and the duration of smoking.  Apart from cigarette smoke, gases 
released from soil and building materials, environmental exposure to cancer hazardous gases, 
asbestos, paint, organic chemicals and Cr, As, Cd like metals, air pollution and radiation cause 
lung cancer among people. Family history and the medical history of tuberculosis may increase 
the risk factor for lung cancer.3 
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 1.7.3 Diagnosis 
Recent studies prove that the chest x-ray screenings do not reduce the mortality rate of lung 
cancer patients.53 Modern tests such as low-dose spiral computed tomography (CT)3 and molecular 
markers53 in sputum are found to be better techniques to detect lung cancer in their early stages. 
National Lung Screening Trial results show 20% fewer lung cancer deaths among  lung cancer 
patients (heavy smokers) who went through spiral CT screenings compared to normal chest x-ray 
screenings.3 
Screening of high risk individuals enhances lung cancer survival rates by diagnosing the 
disease at an early stage, which makes treatments more successful. It has been estimated that at 
least 8.6 million Americans, who are considered as high risk lung cancer patients should receive 
low-dose CT scans annually.54 It is possible to prevent over 13,000 deaths if the half of these high 
risk individuals have been tested via low-dose CT scans.55 
 
 1.7.4 Treatments 
There are few stages of a lung cancer. Non-small cell lung cancer and small cell lung 
cancer.55 Non-small cell lung cancers are diagnosed as 4 different stages from stage I to stage IV, 
depending on disease progress.  Stage I is where the cancer is confined to the lung. In stage II and 
III, cancer can be seen in lung as well as in lymph nodes. Stage IV is the stage where cancer is 
spread away from lungs and has moved to other organs of the body (e.g. liver or brain). 
Treatments are strictly dependent on the type and the stage of the lung cancer.3 Surgery, 
radiation therapy, chemotherapy and some other targeted therapies are the few treatment methods 
currently used. Surgeries are commonly performed for the localized non-small cell lung cancers. 
Radiation therapy and chemotherapy will be usually done after a surgery, because it improves the 
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survival rate.  Patients who have advanced (stage III and IV) non-small cell lung cancer are 
normally treated with targeted drugs and chemotherapy. For small cell lung cancer patients, 
chemotherapy alone or combination with radiation are the most common treatments available.3 
 
 1.7.5 Survival and Mortalities 
Statistical data shows that the 1 year relative survival for lung cancer has increased from 
37% in between 1975-1979 to 43% in between 2003-2006.3 However, the 5 year survival rate for 
all stages in lung cancer has been estimated to be 15%. For small cell lung cancer, the 5 year 
survival rate is about 6%, while for non-small cell lung cancer is about 17%.56 
According to the studies, developing a lung cancer in male smokers is 23 times higher and 
in female smokers it is about 13 times higher compared to nonsmokers.56 As mentioned earlier, 
lung cancer is the main contributor to the cancer related mortalities in the United States and 
surpassed colon cancer in men and breast cancer in women in the early 1950s and early 1980s, 
respectively. 
According to the statistics, men from age 40 years onward have a high risk of mortality 
due to lung cancer compared to the other cancer related mortalities. For women lung cancer 
mortality surpasses breast cancer mortality at age 60 years and older.57 
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Figure 10: Trends in Death Rates Among Males for Selected Cancers, United States, 1930 
to 2008 (Taken with permission of Reference 57) 
 
 1.7.6 Lung Cancer and Proteases 
There are many proteases involved in lung cancer development and tumor generation. We 
have discussed three main protease categories in section 1.5. Most of those proteases play major 
roles in lung cancer development.  
Urokinase-type plasminogen activator (uPA) is overexpressed in lung carcinomas in 
stromal and cancer cells.58 In non-small-cell, non-NE (neuroendocrine) carcinomas, stromal 
expression of uPA and MMP-11 was amounting to 80 to 90% of the expression in the whole 
tumor.59 Studies showed that uPA overexpression is detected in stromal fibroblasts and in tumor 
cells in both non-small cell lung carcinomas and neuroendocrine lung tumors.60 Epithelial 
expression of uPA in non-small cell lung carcinomas is linked to the presence of node metastasis 
and expression in fibroblasts was correlated to the tumor size.60 
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In matrix metalloproteinases, MMP-2 (gelatinase A) and MMP-9 (gelatinase B) were 
expressed in lung cancer tumor cells.61  Also, in  non-small cell lung carcinomas MMP-1, MMP-
9 and MMP-11 were found in tumor samples.62 Tokuraku et al. reported a matrix metalloproteinase 
(MT-MMP or MMP-14) which is expressed on the cell surface. It is capable of activating MMP-
2.  A correlation between MMP-2 expression in tumor tissue and expression of MT-MMP (MMP-
14) was discovered. MMP2 also correlates with lymph node metastases.63 Analysis of human lung 
tumor tissues indicated that MMP-1 and MMP-10 are overexpressed in lung tumors, but MMP-7 
is detected in lower concentrations.64 
Cathepsin S has been analyzed in tissue cytosols of lung parenchyma, lung tumors and 
lymph nodes by using ELISA. The levels of Cathepsin S in lymph nodes were significantly higher 
compared to lung parenchyma or tumors.3 Studies on the cysteine proteinases, Cathepsin L and 
Cathepsin B indicated that they are involved in tumor progression and angiogenesis, because they 
are able to degrade extracellular matrix proteins.65  
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Chapter 2 - Early Detection of Pancreatic Cancers in Liquid Biopsies by 
Ultrasensitive Fluorescence Nanobiosensors 
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 2.1 Abstract 
Numerous proteases, such as matrix metalloproteinases (MMP's), cathepsins (CTS), and 
urokinase plasminogen activator (uPA), are either dysfunctional, over- or under-expressed in solid 
tumors, when compared to healthy human subjects. This offers the opportunity to detect early 
tumors in liquid biopsies, such as serum. This approach is of particular advantage for the early 
detection of pancreatic cancer, which is a “silent killer”, because it shows only distinct symptoms 
at the distant stage when the survival rates are especially low.  
We have developed fluorescence nanobiosensors for ultrasensitive (sub-femtomolar) 
protease detection, consisting of water-dispersible Fe/Fe3O4 core/shell nanoparticles and two 
tethered fluorescent dyes:  tetrakis(4-carboxyphenyl)porphyrin (TCPP) and cyanine 5.5. These 
nanobiosensors exhibit both, dipole-surface energy transfer (SET) quenching and Förster 
Resonance Energy Transfer (FRET) of tethered TCPP. Upon enzymatic cleavage, the fluorescence 
of TCPP increases, which enables the detection of numerous proteases at sub-femtomolar 
activities.  
Additionally, we have tested a recently tested arginase sensor as well. The major difference 
in design is that the tether between Fe/Fe3O4 and TCPP is not cleaved, but biochemically altered 
by arginases I + II.  The change in tether dynamics then leads to an increase of TCPP fluorescence, 
thus permitting the detection of arginase activity. 
We have identified a protease/arginase signature for the detection of pancreatic 
adenocarcinomas in serum, consisting of arginase, MMPs -1, - 3, and -9, cathepsins -B, and -E, 
urokinase plasminogen activator and neutrophil elastase. This is a potential game-changer in 
pancreatic cancer detection. 
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 2.2 Introduction 
Pancreatic Cancer is the third leading cancer in the United States, with a 5-year survival 
rate of less than 6%. In 2016, in the U.S. alone there were an estimated 53,070 new cases of 
pancreatic cancer and 41,780 deaths.66 Pancreatic cancers are markedly on the increase over the 
past three decades. Despite the high mortality rate associated with pancreatic cancer, its etiology 
is poorly understood.67 Pancreatic cancer has one of the worst prognoses of all gastrointestinal 
malignancies.  
The symptoms are not easily detectable (only 7% of cases are detected at stage I, virtually 
no cases are detected at stage 0), and there is to date no reliable screening test for pancreatic cancer. 
Detection is usually accomplished in an advanced-stage, leading to a very poor prognosis. The 
development of a feasible early warning test for pancreatic cancer would not only save lives, it 
would also have a positive impact on the projected health care costs in the US.68 
Many cases are already in well-advanced stages of metastases and dissemination with 
peripheral invasion of the retroperitoneum, vascular system, or nerves when pancreatic cancer is 
diagnosed. The rate of resection is <15% and the 5-year survival rate is 7–25% in the curative 
resected cases.69,70 In the majority of cases, recurrences from pancreatic cancer are liver metastases 
and peritoneum dissemination.70,71 It is well established that surgical treatment for liver metastases 
from pancreatic cancer cannot offer long-term survival for the vast majority of patients. 
Additionally, the outcomes of radiotherapy and chemotherapy are equally unfavorable.72 
Pancreatic ductal adenocarcinoma (DAC, 85-90% of all cases) is characterized by desmoplasia, 
which is the abundance of extracellular matrix (ECM) containing collagen, fibronectin, 
proteoglycans, and hyaluronic acid, as well as catalytically active enzymes and proteinases.70 The 
accumulation of ECM components alters the architecture of pancreatic tissue causing abnormal 
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configurations of blood and lymphatic vessels leading to poor perfusion.70 This effect is ultimately 
responsible for the inefficacy of classic chemotherapy against DAC.70 Based on data from the 
National Cancer Data Base (1992-2004, statistics last revised on 09/15/2016), the 5-year observed 
survival for exocrine pancreatic cancer is 14% when the cancer was discovered at stage IA, 12% 
at IB, 7% at IIA, 5% at IIB, 3% at III, and 1% at stage IV. Endocrine pancreatic cancers show 
higher survival rates: 61% at stage I, 52% at II, 41% at III, and 15% at stage IV.73 Note that this 
data is for patients who have received surgery. All stages used here were defined in accordance 
with the American Joint Committee on Cancer (AJCC) TNM staging system.74 
Approximately 96% of all pancreatic cancers are exocrine. They comprise of 
adenocarcinomas (more than 90% of all pancreatic cancers), adenosquamous carcinomas, 
squamous cell carcinomas, signet ring cell carcinomas, undifferentiated carcinomas, 
undifferentiated carcinomas with giant cells, and solid pseudopapillary neoplasms of the 
pancreas.75 The only viable strategy to distinguish between these cancer types to date is their 
position within the pancreas and the histological identification of the cell type. Pancreatic 
neuroendocrine tumors/carcinomas, or islet cell tumors, are uncommon (approx. 4% of pancreatic 
tumors). Among them are insulinomas, gastrinomas, glucagonomas, somatostatinomas, VIPomas 
(VIP: vasoactive intestinal peptide), PPomas (PP: pancreatic polypeptide) and carcinoid tumors. 
Insulinomas and gastrinomas are the most common. Although pancreatic neuroendocrine 
tumors/carcinomas are less aggressive than exocrine pancreatic cancers, the differentiation 
between benign neuroendocrine tumors (50%) and aggressive neuroendocrine cancers (50%) 
solely based on histological results is challenging.76 
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 2.2.1 Liquid Biopsies 
Detecting cancer and other diseases by means of a simple blood test has become a realistic 
possibility. Virtually all competing companies, among them Personal Genome Diagnostics77, 
Genomic Health78, Myriad Genetics79, Guardant Health79 and Pathway Genomics79 rely on PCR 
to detect genetic mutations, and various RNA’s that are overexpressed in tumors. In sharp contrast, 
the approach discussed here focuses on detecting the protease/arginase80-82 signature of various 
solid tumors (breast81, non-small lung82 and pancreatic cancers (reported here)). Including blood 
tests for the estimated 14.5 million cancer survivors in the United States, the market potential for 
liquid biopsies is currently estimated to more than $20 billion a year. The average genomic test is 
currently between $5,000 and $6,000, which may prove prohibitively expensive for many patients. 
Compared to the state-of-the-art in liquid biopsies, protease profiling using the proposed approach 
will result in significantly reduced costs: $100 to $200 per protease/arginase profile for the end-
user appears to be realistic. It should also be noted that there is a high potential for synergy between 
genomic and proteomic tests: genetic tests often show the potential for disease development, but 
not exactly when the transition to a tumor actually occurs.  Protease/arginase assays can do exactly 
that. 
 
2.2.2 Standard of care in detecting pancreatic cancer  
The standard of care is based on symptoms, which are developed only when pancreatic 
cancer has progressed.83 Nonspecific symptoms of exocrine pancreatic cancer are jaundice or 
diabetes. Pancreatic neuroendocrine tumors can have a variety of symptoms, among them stomach 
ulcers, diabetes, hypoglycemia, glossitis, diarrhea, and gallbladder problems. If unspecific 
symptoms exist or any masses or fluid buildup have been detected, state-of-the-art imaging 
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methods, such as Computed Tomography (CT scans), Magnetic Resonance Imaging (MRI), 
Positron emission tomography (PET), Ultrasonography (ultrasound or US) or more specialized 
methods (e.g. Somatostatin receptor scintigraphy (SRS) and Endoscopic retrograde 
cholangiopancreatography (ERCP)) will be used. Although the information that is obtainable by 
using these different methods is important with regard to therapy decisions, none of these methods 
is capable of routinely detecting in-situ pancreatic cancers, because the pancreas is obscured by 
other organs, making the detection of tumors with volumes of 1-5 mm3 difficult.84 
There are three types of common pre-cancerous lesions for pancreatic cancer, 
"Pancreatic Intraepithelial Neoplasia" or PanINs, Intraductal Papillary Mucinous Neoplasms 
(IPMNs) and "Mucinous Cystic Neoplasms" or MCNs.85 
 
Figure 11: The location of the pancreas obstructs early in-vivo diagnostics 
 
Blood tests for pancreatic cancer have been focusing on CA19-9 (carbohydrate antigen 19-
9)86, CEA (carcinoembryonic antigen)87 and recently K-ras gene mutations.88 These tests are not 
suitable for the detection of in-situ pancreatic cancers. CA19-9 is overexpressed in many types of 
gastrointestinal cancer (e.g. colorectal cancer, esophageal cancer, and hepatocellular carcinoma), 
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but it is also elevated during pancreatitis, cirrhosis, and other diseases in which inflammation 
occurs, resulting in numerous false positives. 86 False negatives also arise frequently due to genetic 
factors, especially in the Caucasian population. Therefore, the American Society of Clinical 
Oncology discourages the use of CA19-9 in screening for tumors.89 Besides tumors, CEA 
(carcinoembryonic antigen) concentrations in the blood of adults are known to be influenced by 
numerous factors, many of them unrelated to cancer. Although the genetic landscape of pancreatic 
cancer shows nearly ubiquitous mutations of K-ras, the detection of oncogenic K-ras mutations 
alone is not sufficient to lead to pancreatic ductal adenocarcinoma (PDAC) in either human or in 
genetically modified adult mouse models.90  
 
 2.2.3 The Protease Web in Healthy and Cancer Patients 
Matrix metalloproteinases (MMPs), serine proteases and cysteine proteases have well-
documented roles in malignant progression, including angiogenesis, invasion, and metastasis.91 It 
is of importance that tumor-promoting proteases act as a part of an extensive multidirectional 
network of proteolytic interactions. There are 570 known human proteases, coupled with a smaller 
group of endogenous protease inhibitors that tightly regulate their activity.92 In general, cathepsin 
B, urokinase plasminogen activator (uPA), metallo-proteinases (MMP), occupy central nodes for 
amplifying proteolytic signals passing through the network. Recent research has shown that this 
proteolytic signaling network interacts with other important signaling networks, such as 
chemokines, cytokines, and kinases.91 Understanding this extensive network of proteolytic 
interactions as a system of activating and inhibiting reactions may prove to be an important key to 
unlock tumor biology.  
Urokinase plasminogen activator (uPA) is a very specific protease that binds to its 
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receptor, uPAR, and cleaves the inactive plasminogen to the active plasmin. This is the first step 
in a well-known protease cascade that causes angiogenesis. Therefore, uPA is associated with 
angiogenesis in tumors. It is also very active in tumor metastasis. Plasmin is a somewhat non-
specific protease that goes on to cleave many targets including activating pro-collagenases, 
degrading the extracellular matrix (ECM), and releasing/activating growth factors. uPA has been 
identified as a target in clinical trials for advanced breast and pancreatic cancer.93 
 
 
Figure 12: Dysfunctional proteolytic networks in cancer91  
Figure 12 emphasizes the principles of protease biochemistry, but it is by no means 
comprehensive. Further interlinked protease networks exist. Proteases in red have been used 
successfully for the detection of early solid tumors (Tables 4 and 5). 
Cathepsins, with a few exceptions, are cysteine proteases.94 Often found in the 
lysosomal/endosomal pathway, cathepsins usually operate at low pH values, but many are able to 
retain some activity at neutral pH. Cathepsins are either largely overexpressed or misexpressed by 
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cancerous cells, causing activation outside of the cells. This activation outside of the cell can cause 
ECM degradation and initiate known ECM degradation cascades. For instance, cathepsin B is 
known to activate uPA.91 Cathepsins are highly up-regulated in pancreatic cancer and contribute 
to the development and progression of the cancer phenotype.73,94-96 
 
 2.2.4 Diagnostic Strategy in Liquid Biopsies 
Our diagnostic strategy is based on the paradigm that protease networks in pancreatic 
cancer are dysfunctional. However, some proteases are known to be context-specific, which adds 
to the complexity. For instance, down-regulation of cathepsin L is known to inhibit pancreatic islet 
cell carcinogenesis97, but enhances epidermal tumor progression.98 Several MMPs (-3, -9, -11) are 
known to either impair99 or promote100 tumor progression, depending on cell type and tumor 
microenvironment.  
 
 2.3 Gene Expression Analysis 
Gene Expression Analysis101 is straightforward approach to determine the proteases that 
are overexpressed in solid tumors, such as pancreatic cancer. A wealth of data is available from 
databases, such as NCBI GEO, Entrez Gene ID, Unigene ID and Gene Symbol.101 This strategy is 
able to select protease candidates that have a high probability of being proximal biomarkers for 
pancreatic cancer from the total of 570 proteases that are known from the human genome.92 This 
makes the selection process far less arbitrary that it would have to be based on protease-related 
cancer literature alone.  
The relevant datasets for this study were obtained from the publicly accessible NCBI GEO 
database.102 Criteria for datasets included in the analysis were that the investigated species is homo 
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sapiens and that the dataset contains samples from both primary tumor samples and healthy human 
tissue. The fold change of gene expression is taken as an indicator of the up- or downregulation of 
the genes of interest and R was used to extract the relevant raw data, calculate p-values and 
generate boxplots to illustrate data-ranges.103,104 
Arginase is found in mammalian bodies in two isoforms: arginase I (L-arginase 
ureahydrolase, AI, UniProt P05089) and arginase II (AII, UniProt P78540). Arginase I and II share 
61% amino acid sequence identity.105 Arginase I is a liver enzyme106, whereas arginase II is found 
in tissue.107 From the data summarized in Figure 13, arginase II is a more suitable candidate for 
pancreatic cancer detection, if this tissue enzyme is able to find its way into the bloodstream in 
sufficient concentrations. Unfortunately, the sensor for arginase activity developed in the 
Bossmann group won’t be able to differentiate between arginase I and II.80  
 
Figure 13: Statistical genetic expression analysis of Arginases I and II in primary tumor 
samples and healthy human tissue (group sizes: n(ARG I) = 117, n(ARG 2) =117). All data 
were obtained from the NCBI GEO database.102 Bar graph (left, showing means and 
standard deviations) and box plot (right, indicating the observed data range). PC: primary 
pancreatic cancer tissue. Control: apparently non-cancerous tissue from the same patient. 
 
From the data shown in Figure 14, cathepsin B appears to be an excellent candidate, which 
is in agreement with numerous reports in the literature.73,94,95,97,108-111 Cathepsin B won’t be 
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specific for pancreatic cancer, because it is also enhanced in breast and lung cancer. However, it 
can be an important component of a panel of enzymes for early cancer detection.  
 
 
Figure 14: Statistical genetic expression analysis of Cathepsin B in primary tumor samples 
and healthy human tissue (group sizes: n(CTS B) = 117). All data were obtained from the 
NCBI GEO database.102 Bar graph (left, showing means and standard deviations) and box 
plot (right, indicating the observed data range). PC: primary pancreatic cancer tissue. 
Control: apparently non-cancerous tissue from the same patient. 
 
 
 
Figure 15: Statistical genetic expression analysis of Cathepsin D in primary tumor samples 
and healthy human tissue (group sizes: n(CTS D) = 117. All data were obtained from the 
NCBI GEO database.102 Bar graph (left, showing means and standard deviations) and box 
plot (right, indicating the observed data range). PC: primary pancreatic cancer tissue. 
Control: apparently non-cancerous tissue from the same patient. 
 
According to the data summarized in Figure 15, cathepsin D appears to be a slightly better 
candidate for detecting pancreatic cancer than cathepsin B. However, since this data is obtained 
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from primary cancerous tissue and apparently healthy tissue from the same patient, it does not 
exactly reflect the different expression pattern in truly healthy and pancreatic cancer patients.  
The gene expression analysis performed here (Figure 16) clearly identified cathepsin E as 
the best candidate for pancreatic cancer detection.  
 
 
Figure 16: Statistical genetic expression analysis of Cathepsin E in primary tumor samples 
and healthy human tissue (group sizes: n(CTS E) = 117). All data were obtained from the 
NCBI GEO database.102 Bar graph (left, showing means and standard deviations) and box 
plot (right, indicating the observed data range). PC: primary pancreatic cancer tissue. 
Control: apparently non-cancerous tissue from the same patient. 
 
Both, urokinase-plasminogen-type activator (uPA)112 and urokinase-plasminogen 
receptor113 exist in multiple isoforms. Depending on the location where uPA is active, we decide 
between uPA (all isoforms which can be found in blood) and uPA-tissue type, which comprises 
all isoforms found in tissue. As shown in Figure 17, uPA-tissue type is most promising as 
biomarker for pancreatic cancer. However, the nanobiosensors in the Bossmann group are not yet 
able to differentiate between the uPA isotypes. Furthermore, uPA-tissue type has to migrate into 
the bloodstream before it can be detected besides uPA in liquid biopsies based on serum. During 
the recent years, the uPA-Receptor isoforms in blood and tissue have become the target of great 
interest113, because they appear to be proximal biomarkers for metastases in numerous solid 
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tumors.114 The Bossmann group is currently working on supramolecular detectors, which will be 
able to detect the uPA receptor in the future.  
 
 
Figure 17: Statistical genetic expression analysis of urokinase-plasminogen activators 
(uPA’s), urokinase-plasminogen activators receptor and uPA – tissue type in primary tumor 
samples and healthy human tissue (group sizes: n(uPA) = 117, n(uPA tissue) = 117, n(uPA 
receptor = 117). All data were obtained from the NCBI GEO database.102 Bar graph (left, 
showing means and standard deviations) and box plot (right, indicating the observed data 
range). PC: primary pancreatic cancer tissue. Control: apparently non-cancerous tissue 
from the same patient. 
 
MMP-1 is a marker for tissue remodeling and, therefore, overexpressed in numerous solid 
tumors.115 It has been found to be a proximal marker for non-small-cell-lung cancer as well.82  
 
Figure 18: Statistical genetic expression analysis of Matrix Metalloproteinase 1 (MMP-1) in 
primary tumor samples and healthy human tissue (group sizes: n(MMP-1) = 117. All data 
were obtained from the NCBI GEO database.102 Bar graph (left, showing means and 
standard deviations) and box plot (right, indicating the observed data range). PC: primary 
pancreatic cancer tissue. Control: apparently non-cancerous tissue from the same patient. 
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MMP-3 has been recently proposed as a prognostic factor for poor survival in pancreatic, 
pulmonary, and mammary carcinoma.116 Furthermore, MMP-1, -2, -3, -7. -11 (not tested here), 
and MMP-13 (not tested here) are implicated in inflammation-induced epithelial-to-mesenchymal 
transitions (EMT).117 
 
 
 
Figure 19: Statistical genetic expression analysis of MMP-3 in primary tumor samples and 
healthy human tissue (group sizes: n(MMP-3) = 117). All data were obtained from the NCBI 
GEO database.102 Bar graph (left, showing means and standard deviations) and box plot 
(right, indicating the observed data range). PC: primary pancreatic cancer tissue. Control: 
apparently non-cancerous tissue from the same patient. 
 
 
Figure 20: Statistical genetic expression analysis of MMP-9 in primary tumor samples and 
healthy human tissue (group sizes: n(MMP-9) = 117). All data were obtained from the NCBI 
GEO database.102 Bar graph (left, showing means and standard deviations) and box plot 
(right, indicating the observed data range). PC: primary pancreatic cancer tissue. Control: 
apparently non-cancerous tissue from the same patient. 
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In previous studies, MMP-9 was  found in excess amounts in pancreatic cancer tissue 
samples with compared to the normal pancreatic tissue samples.45  
Neutrophil elastase has been included into this panel, because it was predicted that it will 
be less active in tumor tissue than in presumably healthy tissue of the same patient. This offers the 
opportunity to further experimentally test the predictions of statistical genomic expression 
analysis. Neutrophil elastase is produced by active neutrophils and a mediator of the innate 
immune system.118 However, tumor tissue is highly immune-depressed, as characterized by high 
arginase activity.80 Therefore, it can be expected that neutrophil elastase activity is low in 
pancreatic tumor tissue. 
 
 
Figure 21: Statistical genetic expression analysis of neutrophil elastase (NE) in primary 
tumor samples and healthy human tissue (group sizes: n(NE) = 117). All data were obtained 
from the NCBI GEO database.102 Bar graph (left, showing means and standard deviations) 
and box plot (right, indicating the observed data range). PC: primary pancreatic cancer 
tissue. Control: apparently non-cancerous tissue from the same patient. 
 
In Table 4, the ID’s, p-values119 and logFC (down- or up-regulation of genes) for the group 
of target proteases in pancreatic cancer tissue samples are summarized.103,104 It should be noted 
again that this data is obtained from comparing the protease expression levels in primary pancreatic 
tumors and apparently healthy tissue samples from the same patients. Since cancer is a systemic 
disease, it cannot be expected that all of these correlations can be verified by measuring the activity 
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(not the concentration) of proteases in a group of pancreatic cancer patients and a group of age-
matched healthy volunteers. Much more likely, also noncancerous tissue will be affected by a 
tumor somewhere in the patient’s body, because this tumor is connected to the blood supply 
starting from stage I. 91,120,121    
 
Table 4: NCBI GEO ID’s, p-values119 and logFC (down- or up-regulation of genes) for the 
group of target proteases in pancreatic cancer tissue samples.103,104 
ID P-Value logFC 
Gene 
symbol 
Gene title 
Arginase 2 
7975268 4.20E-02 0.17303 ARG2 Arginase 2 
Cathepsin B 
8149330 3.18E-07 0.848623 CTSB Cathepsin B 
Cathepsin D 
7945666 5.64E-07 0.534505 CTSD Cathepsin D 
Cathepsin E 
7909164 6.00E-15 2.684101 CTSE Cathepsin E 
uPA 
7928429 2.54E-10 1.374367 PLAU Plasminogen activator, urokinase 
8037374 7.25E-07 0.843846 PLAUR Plasminogen activator, urokinase receptor 
MMP1 
7951271 1.96E-04 1.225159 MMP1 Matrix metallopeptidase 1 
MMP3 
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7951284 1.93E-05 0.66726 MMP3 Matrix metallopeptidase 3 
MMP9 
8063115 5.12E-09 1.116676 MMP9 Matrix metallopeptidase 9 
Neutrophil Elastase 
8024056 8.87E-02 -0.09965 ELANE Elastase, neutrophil expressed 
 
 2.4 Synthesis and Validation of Ultrasensitive Nanobiosensors for Protease 
and Arginase  
A detailed account of the Bossmann group’s recent development of Fe/Fe3O4 nanoparticle 
based diagnostic nanobiosensors is given in references.80,81,122,123 Fe/Fe3O4 nanoparticles are 
synthesized by thermal decomposition of Fe(CO)5.
122,124,125 The nanoparticles have a well-defined 
core/shell structure, with the average Fe(0) core diameter of 13 +/- 0.5 nm and the Fe3O4 shell 
thickness of 2.0 ± 0.5 nm, respectively.122 Dopamine forms robust organic coatings with binding 
constants of the order of 1015 l mol-1.126 It also increases the water-solubility of the resulting 
nanoplatforms to > 5g L-1.126 Porphyrins have been used as cleavable fluorescent dyes, because 
their photophysical properties are well characterized.127 Cyanine 5.5 has been co-attached as FRET 
quencher due to its large molar extinction coefficient.128 Figure 22 shows the structure of the 
nanoplatform comprised of dopamine-coated Fe/Fe3O4, consensus sequence, TCPP, and Cy 5.5. 
In Table 5, the consensus sequences that will be employed for detecting the selected proteases129, 
as well as the peptide tether for measuring arginase80, are summarized. Cyanine 5.5 is permanently 
linked to dopamine without using an enzyme-cleavable tether. The optimal average density of 
cyanine 5.5, which is directly bound to the dopamine units, and TCPP, which is tethered via 
oligopeptide, was determined to 50+/-4 (Cy 5.5) and 35+/-3 (TCPP) per nanoparticle, following a 
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random-deposition based modelling approach130, assuming a core/shell structure, with average 
Fe(0) core diameter of 13 +/- 0.5 nm and Fe3O4 shell thickness of 2.0 +/- 0.5 nm, respectively.To 
date, the Bossmann group has scaled up the synthesis of the nanobiosensors to the 5g stage.  
The nanoplatforms are activated via enzymatic cleavage or posttranslational modification 
of the tether between central nanoparticle and dye, which leads to increased TCPP-fluorescence 
(light switch effect, see Figure 23).122 
 
 
Figure 22: Chemical structure of the nanobiosensors for protease and arginase detection 
 
Figure 22 shows the core of the nanobiosensor consists of dopamine-coated a Fe/Fe3O4 
core to which 50+/-4 cyanine 5.5  and 35+/-3 TCPP molecules are bound, following a random-
deposition based modelling approach.130 The consensus sequences experience proteolytic cleavage 
by their respective proteases, whereas the chemical constitution of the posttranslational 
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modification sequence is changed. For instance, arginases I + II convert arginine to ornithine 
without proteolytic cleavage of the oligopeptide.80 
Due to the inferior scattering properties of Fe(0)-nano-particles (compared to Ag and 
Au)131, the limits of detection (LOD) when using central Fe/Fe3O4-nano-particles in optical 
nanobiosensors are significantly lower. For all MMPs and cathepsins use here, sub-femtomolar 
limits of detection (LOD) have been realized.122,132 After optimization, ten repetitions of the 
calibration procedure established a relative error under 2%, which is sufficient for clinical 
applications. 
 
 
 
Figure 23: A: Function principle of nanobiosensors for protease detection: the consensus 
sequence is cut by the protease; B: Function principle of nanobiosensors for posttranslational 
modification: the chemical identity of amino acids in the linker is changed via enzymatic 
reaction; C: Typical emission spectra occurring from the nanosensor for MMP-3 after 1h of 
incubation at 37oC (𝝀exc = 421nm). a: buffer; b: nanosensor in HEPES buffer after 1h of 
incubation at 37oC; c: nanosensor after 1h of incubation with MMP-3 at 37oC. 
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 2.5 Methods 
 2.5.1 Nanobiosensor Synthesis 
The synthesis of the nanobiosensors has been performed according to established and 
published procedures.80,122,125,132 In short, water-dispersible Fe/Fe3O4 nanoparticles featuring 
dopamine ligands126, TCPP
122, and cyanine 5.5122 were synthesized according to established 
procedures.  
Oligopeptides were synthesized by means of solid phase peptide synthesis on 2-chlorotrityl 
resin.125,133 Three equivalents of Fmoc (N-(9-fluorenyl)methoxycarbonyl) protected amino acid and 
HBTU were dissolved in a DIEA/DMF solution, and added to the 2-chlorotrityl resin preloaded 
with 0.20 mmol of amino acid per g. The solution was drained from the resin after 30 minutes of 
reaction. This process was repeated one more time. Then, the Fmoc group of the newly introduced 
amino acid was removed by using 20% (v/v) piperidine in DMF. Following this procedure, 
stepwise addition of Fmoc-protected amino acids resulted in the desired peptides. The consensus 
sequences used are summarized in Table 5. TCPP has been connected to the N-terminal end of the 
oligopeptides while it was still on the resin. The TCPP-oligopeptide was then cleaved off the resin 
and linked to the primary amine groups of Fe/Fe3O4-bound via an amide bond.
122 Note that these 
sequences also contain GAG and AG as peptide spacers at the N- and C-terminal ends of the 
oligopeptides to facilitate easier access by the enzymes to their respective consensus sequence. 
The oligopeptides have been purified by quantitative HPLC if their purity did not exceed 90%, as 
determined by analytical HPLC.80,81,122 Their chemical identity has been confirmed by MALDI-
TOF.1-3 Nanobiosensors were assembled according to the published procedures80,122,125,132 and the 
separation of the nanobiosensors from unreacted low molecular weight components, dyes, and 
oligopeptides, will be achieved via dialysis (cut-off: 5,000 Da). After subsequent lyophilisation, 
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the resulting nanobiosensors have a shelf-life of at least 2 years when stored under argon between 
+ 4 and – 80oC. 
 
Table 5: Peptide Sequences for Nanobiosensors129  
 
 
 
 
 
 
 
 
Peptide sequences are written in single-letter code. 
 
2.5.2 Fluorescent Plate Reader Measurements: Calibration and Validation 
A BioTek Synergy 2 plate reader (tungsten halogen lamp, excitation bandpass filter: 421 ± 
10 nm, analysis bandpass filter: 650 ± 25 nm) with 96-well plates was used. Solution (1) HEPES 
buffer (25 µmol) (2-[4-(2-hydroxyethyl) piperazin-1-yl]ethanesulfonic acid) was prepared 
enriched with Ca(II), Mg(II), and Zn(II) (10 µmol each) at 298 K (pH=7.2) to ensure full enzymatic 
activities. Solution (2) containing the Fe/Fe3O4 based nanobiosensor was prepared by dissolving 
0.30 mg of the selected nanobiosensor in 1.0 mL of HEPES buffer by sonication for 10 min at 298 
K. The following samples were prepared and plated by adding solution (1) or solution (2) to 5 µL 
of serum/protease sample; A: Sample Control (125 µL of solution (1) + 5 µL serum/protease 
sample); B: Assay (125 µL of solution (2) + 5 µL of serum/calibration solution containing known 
Nanobiosensor Oligopeptide Tether 
MMP 1 GAGVPMS-MRGGAG 
MMP 3 GAGRPFS-MIMGAG 
MMP 9 GAGVPLS-LYSGAG 
uPA GAGSGR-SAG 
Cathepsin B (CTS B) GAGSLLKSR-MVPNFNAG 
Cathepsin D GAGDSG-LGRAG 
Cathepsin E GAGEVAL-VALKAG 
Neutrophil Elastase GAGGEPV-SGLPAG 
Arginase GAG RRRRRRRAG 
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concentrations of commercially available proteases; C: Assay Control (125 µL of solution (2) + 5 
µL of solution (1)); and D: Blank (130 µL of solution (1)). Each sample (total 130 µL) was loaded 
into one well of 96 wells plates, having at least three replicates of each assay per serum/protease 
sample. Solutions were incubated at 310 K for 60 min, followed by detection of nanoplatform 
fluorescence at 298 K utilizing a 96-well fluorescence plate reader. Matrix effects have been 
previously evaluated by using heat-inactivated combined sera from the control group of healthy 
volunteers. The results were previously published.81 Heat inactivation of serum was performed 
according to established procedures.134 Whereas in previous analyses of the protease activities in 
serum, we have calculated the protease activity for each measured protease, the main focus of this 
study was on developing a quick fluorescence plate-reader method for pancreatic cancer detection, 
which will work reliable in a clinical setting. Therefore, the actual fluorescence signals measured 
by the plate reader were used to calculate the results discussed below.  
 
 2.6 Results and Discussion 
Arginase activity appears to be higher in patients with pancreatic ductal adenocarcinomas 
(DAC) and metastatic pancreatic adenocarcinoma (MAC) than in the control group (Figure 24). 
However, the observed variations are much higher in both groups of pancreatic cancer patients 
than in the apparently healthy control groups. It is noteworthy that arginase activity is about the 
same in healthy and patients having pancreatic neuroendocrine tumors (NET), whereas the 
arginase activity is actually lower in patients with metastatic pancreatic neuroendocrine tumors 
than in the control group. As summarized in Table 6, there are statistically significant differences 
for ductal adenocarcinomas, which have the highest incidence and mortality of all pancreatic 
cancers, and for metastatic neuroendocrine tumors.66   
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Figure 24: Bar graph (left, showing means and standard deviations of fluorescence 
intensities) and box plot (right, indicating the observed data range) for Arginase. Group 
sizes: apparently healthy volunteers: n=48, pancreatic ductal adenocarcinoma (DAC): n=7, 
metastatic adenocarcinoma (MAC): n=9, pancreatic neuroendocrine tumors (NET): n=5, 
metastatic NET (MNET): n=2, all pancreatic cancers (ALL): n = 35. All samples were 
obtained from the Biospecimen Repository Facility of the University of Kansas Cancer 
Center.135 H=age-matched healthy volunteers; PC=pancreatic cancer patients 
 
The variations that are observed in the control groups arise from the age-matching process. 
The same numbers of age-matched healthy volunteers than in the respective cancer groups were 
selected from the control group to avoid an age-bias in the analysis of this data, except for MNET, 
which was too small.  Gene expression analysis predicted upregulation of arginase expression in 
tumors tissue. For two sub-groups, DAC and MAC, we did observe higher arginase activities.   
Cathepsin B expression was lower in all investigated sub-groups of pancreatic cancer, with 
the exception of pancreatic neuroendocrine tumors (NET), where it was slightly higher (Figure 
25). Although the expression patterns were not consistent, the data for both, ductal 
adenocarcinomas (DAC) and neuroendocrine tumors (NET) were statistically significant, whereas 
no significance was calculated for both groups of metastasizing pancreatic cancer. Gene expression 
analysis predicted upregulation of cathepsin B expression. Higher cathepsin B activity was only 
observed in NET, all other groups were lower in activity.  
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Figure 25: Bar graph (left, showing means and standard deviations of fluorescence 
intensities) and box plot (right, indicating the observed data range) for Cathepsin B. Group 
sizes: apparently healthy volunteers: n=48, pancreatic ductal adenocarcinoma (DAC): n=9, 
metastatic adenocarcinoma (MAC): n=9, pancreatic neuroendocrine tumors (NET): n=5, 
metastatic NET (MNET): n=2, all pancreatic cancers (ALL): n = 35. All samples were 
obtained from the Biospecimen Repository Facility of the University of Kansas Cancer 
Center.135 H=age-matched healthy volunteers; PC=pancreatic cancer patients 
 
Although some patients in the sub-groups of ductal adenocarcinoma (DAC), 
neuroendocrine tumors (NET) and metastasizing adenocarcinomas (MAC) were characterized by 
high cathepsin D activities in serum, no statistically significant differences between all four 
pancreatic cancer sub-groups and their respective control groups have been detected. This is 
surprising, because gene expression analysis predicted significant over-expression of cathepsin D 
in pancreatic tumor tissue. This may be an indication that for cathepsin D, there is no good 
correlation between activity in tumor tissue and in blood, or this may have been caused by the 
relatively small group sizes of this study. Another reason for the observed discrepancy is that all 
proteases are being biosynthesized as zymogens (inactive enzymes). They require enzymatic 
activation, usually by another protease. Therefore, cathepsin D, as well as some of the other 
proteases, which do not fit the predicted pattern, may be synthesized in high concentration, but not 
activated.91,95,136  
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Figure 26: Bar graph (left, showing means and standard deviations of fluorescence 
intensities) and box plot (right, indicating the observed data range) for Cathepsin D. Group 
sizes: apparently healthy volunteers: n=48, pancreatic ductal adenocarcinoma (DAC): n=7, 
metastatic adenocarcinoma (MAC): n=9, pancreatic neuroendocrine tumors (NET): n=5, 
metastatic NET (MNET): n=2, all pancreatic cancers (ALL): n = 35. All samples were 
obtained from the Biospecimen Repository Facility of the University of Kansas Cancer 
Center.135 H=age-matched healthy volunteers; PC=pancreatic cancer patients 
 
Genetic expression analysis also predicted that cathepsin E will be an excellent marker for 
pancreatic cancers and over-expressed in tumor tissue. Elevated activity of cathepsin E was found 
in the sera of patients with neuroendocrine tumors (Fiigure 27), whereas in all other three 
pancreatic cancer sub-groups cathepsin E activity was lower than in the respective control groups. 
The data distributions yielded statistically significant differences for pancreatic ductal 
adenocarcinomas (DAC) and neuroendocrine tumors (NET), but not for both groups of 
metastasizing pancreatic cancer. Cathepsin E will be a valuable member of the panel of proteases 
designed for early diagnosis of pancreatic cancer. 
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Figure 27: Bar graph (left, showing means and standard deviations of fluorescence 
intensities) and box plot (right, indicating the observed data range) for Cathepsin E. Group 
sizes: apparently healthy volunteers: n=48, pancreatic ductal adenocarcinoma (DAC): n=7, 
metastatic adenocarcinoma (MAC): n=9, pancreatic neuroendocrine tumors (NET): n=5, 
metastatic NET (MNET): n=2, all pancreatic cancers (ALL): n = 35. All samples were 
obtained from the Biospecimen Repository Facility of the University of Kansas Cancer 
Center.135 H=age-matched healthy volunteers; PC=pancreatic cancer patients 
 
Gene expression analysis correctly predicted the upregulation of urokinase plasminogen 
activator (uPA). UPA’s activity is enhanced in all four patient sub-groups, compared to their 
respective control groups (Figure 28).  However, there is a considerable variability of uPA activity 
within the sub-groups of cancer patients, as well as the apparently healthy volunteers. Therefore, 
only neuroendocrine tumors could be detected with statistical significance. Since uPA has 
numerous functions within the human body91, it is not surprising that its expression pattern varies, 
to a degree, between different human subjects. However, uPA may play a more important role 
with regard to early pancreatic cancer detection when data obtained from larger patient groups can 
be analyzed in the near future.  
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Figure 28: Bar graph (left, showing means and standard deviations of fluorescence 
intensities) and box plot (right, indicating the observed data range) for urokinase 
plasminogen activator. Group sizes: apparently healthy volunteers: n=48, pancreatic ductal 
adenocarcinoma (DAC): n=7, metastatic adenocarcinoma (MAC): n=9, pancreatic 
neuroendocrine tumors (NET): n=5, metastatic NET (MNET): n=2, all pancreatic cancers 
(ALL): n = 35. All samples were obtained from the Biospecimen Repository Facility of the 
University of Kansas Cancer Center.135 H=age-matched healthy volunteers; PC=pancreatic 
cancer patients 
 
Genetic expression analysis also predicted overexpression of MMP-1 in pancreatic tissue. 
In this case, we were able to find enhanced MMP-1 activity in virtually all sera from pancreatic 
cancer patients. For the group of early pancreatic cancers (ductal adenocarcinomas and 
neuroendocrine tumors), MMP-1 is a proximal biomarker. For the group of metastasizing 
pancreatic cancers, detecting MMP-1 leads to less significant data. Again, the calculation of the p-
values is affected by the relatively small numbers119: metastatic adenocarcinoma (MAC): n=9, and 
metastatic neuroendocrine tumors (MNET): n=2. It is our expectation that statistically significant 
differences between MAC and MNET and their control groups can be seen when larger patient 
cohorts become available.  
54 
 
Figure 29: Bar graph (left, showing means and standard deviations of fluorescence 
intensities) and box plot (right, indicating the observed data range) for Matrix 
Metalloproteinase 1 (MMP-1). Group sizes: apparently healthy volunteers: n=48, pancreatic 
ductal adenocarcinoma (DAC): n=7, metastatic adenocarcinoma (MAC): n=9, pancreatic 
neuroendocrine tumors (NET): n=5, metastatic NET (MNET): n=2, all pancreatic cancers 
(ALL): n = 35. All samples were obtained from the Biospecimen Repository Facility of the 
University of Kansas Cancer Center.135 H=age-matched healthy volunteers; PC=pancreatic 
cancer patients 
 
In agreement with gene expression analysis, MMP-3 activities are enhanced in all four sub-
groups of pancreatic cancer patients (Figure 30). However, only for ductal adenocarcinomas 
(DAC), a statistically significant difference between the cancer and the control group was 
observed. In the other three groups, the differences were systematic, but too small, considering the 
small number of patients in each group (NET, MNET), or the experimental variance was too high 
(MAC). For detecting DAC, MMP-3 was the best biomarker in this study (see Table 6).  
 
 
 
55 
 
Figure 30: Bar graph (left, showing means and standard deviations of fluorescence 
intensities) and box plot (right, indicating the observed data range) for Matrix 
Metalloproteinase 3 (MMP-3). Group sizes: apparently healthy volunteers: n=48, pancreatic 
ductal adenocarcinoma (DAC): n=7, metastatic adenocarcinoma (MAC): n=9, pancreatic 
neuroendocrine tumors (NET): n=5, metastatic NET (MNET): n=2, all pancreatic cancers 
(ALL): n = 35. All samples were obtained from the Biospecimen Repository Facility of the 
University of Kansas Cancer Center.135 H=age-matched healthy volunteers; PC=pancreatic 
cancer patients 
 
 
Figure 31: Bar graph (left, showing means and standard deviations of fluorescence 
intensities) and box plot (right, indicating the observed data range) for Matrix 
Metalloproteinase 9 (MMP-9). Group sizes: apparently healthy volunteers: n=48, pancreatic 
ductal adenocarcinoma (DAC): n=7, metastatic adenocarcinoma (MAC): n=9, pancreatic 
neuroendocrine tumors (NET): n=5, metastatic NET (MNET): n=2, all pancreatic cancers 
(ALL): n = 35. All samples were obtained from the Biospecimen Repository Facility of the 
University of Kansas Cancer Center.135 H=age-matched healthy volunteers; PC=pancreatic 
cancer patients 
 
MMP-9 activity was enhanced in ductal adenocarcinomas, neuroendocrine tumors and 
metastasizing adenocarcinomas, which is in agreement with the prediction from gene expression 
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analysis (Figure 31). However, for all three sub-groups, the differences in MMP-9 activities 
detected in the sera of cancer patients and healthy volunteers were not statistically significant.  
Only for the group of metastasizing neuroendocrine tumors, for which MMP-9 activity was 
decreased, a potential significance could be discerned, as indicated by p = 0.0715 for n=2. 
However, further analyses with larger patient numbers have to be performed to either verify or 
falsify this result. This will depend on the availability of de-identified quality serum samples. 
Genetic expression analysis predicted a decreased activity of neutrophil elastase (NE) in 
tumor tissue. Interestingly and quite contrary to this prediction, NE activity was increased in all 
four sub-groups, compared to their respective control groups (Figure 32). Due to the large 
variations found in both, patient and control groups, statistically significant differences were found 
in none of the sub-groups. Without further experimental data, it is not possible for us to speculate 
about the observed discrepancy between gene expression analysis and protease activity 
measurements. 
 
Figure 32: Bar graph (left, showing means and standard deviations of fluorescence 
intensities) and box plot (right, indicating the observed data range) for Neutrophil Elastase 
(NE). Group sizes: apparently healthy volunteers: n=48, pancreatic ductal adenocarcinoma 
(DAC): n=7, metastatic adenocarcinoma (MAC): n=9, pancreatic neuroendocrine tumors 
(NET): n=5, metastatic NET (MNET): n=2, all pancreatic cancers (ALL): n = 35. All samples 
were obtained from the Biospecimen Repository Facility of the University of Kansas Cancer 
Center.135 H=age-matched healthy volunteers; PC=pancreatic cancer patients 
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The results of all protease/arginase activity measurements are summarized in Table 6, 
which is called “Significance Table”, because it contains the calculated p-values for each 
comparison between the pancreatic cancer sub-groups and their age-matched control groups, as 
well as for the comparison between the groups of all pancreatic cancer patients and all apparently 
healthy volunteers. All pairings of pancreatic cancer (sub-)groups and enzymes, for which a 
significant difference in activity is found (p < 0.05) are shown in green, all pairings for which this 
is not the case, are shown in red. They may become significant when more human subjects become 
available. One combination (MNET/MMP-9) is shown in light green, because it is almost 
significant. 
 
Table 6: Significance Table Pancreatic Cancers:  
DAC: Pancreatic Ductal Adenocarcinoma; NET: Pancreatic Neuroendocrine Tumors;  
MAC: Metastatic Pancreatic Adenocarcinoma; MNET: Metastatic Pancreatic Neuroendocrine 
Tumors 
 
ARG CTS B CTS D CTS E MMP-1 MMP-3 MMP-9 uPA NE 
DAC 0.0227 0.0384 0.3742 0.0229 0.0049 0.0041 0.1370 0.1043 0.3084 
NET 0.1234 0.0266 0.7318 0.0156 0.0426 0.1446 0.1889 0.0472 0.1385 
MAC 0.8583 0.8063 0.3206 0.5352 0.3093 0.2129 0.9322 0.6045 0.4473 
MNET 0.0172 0.3467 0.5111 0.1484 0.4022 0.2053 0.0715 0.3359 0.5391 
ALL 0.0011 0.0003 0.2785 0.0296 0.0018 0.0061 0.0328 1.1E-06 0.0091 
 
In Table 6, the p-values119 obtained for comparisons of the protease/arginase expression 
pattern in each cancer sub-group with those of the healthy control group are tabulated. The 
color green denotes measured fluorescence signals that are different from the control group 
with high significance (p < 0.05). Red denotes all cases where there is no statistically 
significant difference between the cancer (sub)group and the control group can be found. 
Group sizes: apparently healthy volunteers: n=48, pancreatic ductal adenocarcinoma 
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(DAC): n=7, metastatic adenocarcinoma (MAC): n=9, pancreatic neuroendocrine tumors 
(NET): n=5, metastatic NET (MNET): n=2, all pancreatic cancers (ALL): n = 35. All samples 
were obtained from the Biospecimen Repository Facility of the University of Kansas Cancer 
Center.135 ARG: arginase, CTS: cathepsin, MMP: matrix metalloproteinase, uPA: urokinase 
plasminogen activator, NE: neutrophil elastase 
 
 2.7 Conclusions 
All pancreatic cancer patients vs. all volunteers: Owing to the larger groups of human subjects, 
compared to the sub-groups (pancreatic cancer patients: n=35, healthy volunteers: n=48), the p-
values are generally lower. The result from this study is that arginase, cathepsins B and E, MMP-
1, -3, -9, urokinase plasminogen activator and neutrophil elastase are capable of detecting 
pancreatic adenocarcinomas and neutroendocrine tumors at early and distant stages. In the clinical 
practice, this means that this panel of enzymes will be able to detect that a patient has potentially 
pancreatic cancer. Further methods of clinical diagnostics, for instance a CT scanner of high-field 
MRI will then follow to ascertain the patient’s clinical condition.  
 
Pancreatic Ductal Adenocarcinoma (DAC): n=7: As already discussed in detail above, 
pancreatic ductal adenocarcinomas comprise more than 90 percent of all pancreatic cancers.76 
They also possess the lowest survival rate among pancreatic cancers.76 Therefore, detecting them 
early by means of a simple blood test (liquid biopsy) is most desirable. This study has identified a 
panel of five enzymes: arginase, cathepsins B, E, and MMP-1, and -3 that can detect DAC with 
high significance. Detecting pancreatic ductal adenocarcinomas at the earliest possible time has 
the potential to safe numerous patients’ lives.  
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Metastatic Adenocarcinoma (MAC): n=9: For other solid tumors, such as breast81- and non-
small-cell lung tumors82, protease expression increases steadily with tumor stage. Therefore, 
higher stages are easier detectable by means of protease activity measurements. This is not the 
case for metastatic adenocarcinoma. The major reason for this difference is the great variance that 
is observed in this sub-group.  
 
Pancreatic Neuroendocrine Tumors (NET): n=5: Cathepsin B and E, MMP-1 and uPA are 
suitable biomarkers for neuroendocrine tumors. Because this class of pancreatic tumors is much 
less aggressive than pancreatic ductal adenocarcinomas, early detection offers a greater potential 
of saving patents’ lives. 
 
Metastatic Pancreatic Neuroendocrine Tumors (MNET): n=2: Arginase and, potentially, 
MMP-9 are, to date, suitable biomarkers for metastatic neuroendocrine pancreatic tumors. Because 
of the very small group size, conclusions are very limited.  
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Chapter 3 - Early Detection of Non-Small-Lung Cancer in Liquid 
Biopsies by Means of Ultrasensitive Protease-Activity Analysis 
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 3.1 Abstract 
Solid tumors are characterized by dysfunctional protease expression pattern. Consequently, 
numerous proteases, such as matrix metalloproteinases (MMP's), cathepsins (CTS), and urokinase 
plasminogen activator (uPA) are either over- or under-expressed, when compared to the 
proteasome of healthy human subjects. This enables the detection of solid tumors in liquid 
biopsies. We have developed nanobiosensors for ultrasensitive (sub-femtomolar) protease 
detection, consisting of a water-dispersible Fe/Fe3O4 core/shell nanoparticle and attached 
fluorescent dyes tetrakis(4-carboxyphenyl)porphyrin (TCPP) and a cyanine 5.5. Both, the central 
nanoparticle and cyanine 5.5 can quench photoexcited TCPP, which is attached via a protease-
cleavable consensus sequence. The specificity and sensitivity of the nanobiosensors permit the 
accurate measurements of the activities of nine signature proteases in serum samples as small as 5 
μL. This technology can detect non-small-cell lung-cancer at stage 1, which has the potential of 
significantly reducing lung-cancer-mortality because of earlier detection. Principally, this 
technology is working for the detection of virtually all solid tumors, of which many feature distinct 
protease signatures. 
 
3.2 Background 
Despite the tremendous efforts dedicated to cancer prevention, diagnosis and treatment, 
mortality remains unacceptably high. Specifically, lung cancer is the most commonly diagnosed 
deadly cancer worldwide with a disappointing 15% overall 5-year survival rate. This high 
mortality rate is mainly due to the absence of clinical symptoms early in the disease, lack of 
methods for effective screening, the molecular heterogeneity of lung cancer and the lack of 
techniques that can be used to select the optimum therapeutic intervention for the treatment of lung 
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cancer. 137,138 Non-small cell lung cancer (NSCLC) is the most common histological type of lung 
cancer, representing 80% of all lung cancers diagnosed and accounting for over one million deaths 
world-wide each year.139 NSCLC is strongly etiologically linked to smoking/smoke exposure, an 
association that has been well established in large-scale epidemiological studies. These prior 
studies have clearly demonstrated that cigarettes are the greatest risk factor, accounting for 87% 
of lung cancers.139 In addition, environmental or second-hand tobacco smoke is also linked to lung 
cancer.139 Currently more than one billion people around the world are smokers. It is expected that 
more than eight million people will die annually from tobacco-related diseases by 2030 unless 
current trend is reversed.140   
The clinical outcome of treatment for NSCLC is highly dependent on the stage of disease 
at the time of diagnosis. Unfortunately, the vast majority of NSCLC (70%) are diagnosed at 
advanced disease stages with very poor prognosis.3 Typically, 5-year survival rates for NSCLC 
drop from 49% (stage IA) and 45% (IB) to 30% (II), and then rapidly to 14% (IIIA), 5% (IIIB) 
and less than 1% (IV).3 Based on this data, there is a critical need for the development of analysis 
methods that are capable of detecting NSCLC (and other lung cancers) at its earliest stages. 
     Since the 1970s, researchers have investigated whether chest radiography can be used for 
screening and early detection of lung cancer.  Later in the 1990s, high resolution CT scans 
produced significant improvement in the outcome for thoracic resection for lung cancer.  However, 
similar to chest x-rays, the use of CT imaging has not been widely adopted. Reasons for this 
include 1) the high cost of CT scans, 2) the clinical expertise needed for their interpretation, 3) the 
safety concerns that the high prevalence of false positives result in surgical interventions in patients 
who do not actually suffer from lung cancer and 4) the lack of availability of this technique in 
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resource-limited environments.141 Consequently low-dose CT is only used as a screening tool in 
very high-risk populations. 
Thus, it is well-accepted by the medical community that new screening tools that will allow 
for non-invasive, cost effective and reliable screening of NSCLC need to be developed and 
translated to the clinic for earlier detection and improved treatment of lung cancer.142 
 
 3.2.1 Competing Technologies 
The recognition of the need for the development of molecular-based screening techniques and 
liquid-based biopsy approaches that can be used to detect and quantify early changes that are 
known to accompany the onset of lung cancer before malignant changes has resulted in the 
development of promising techniques for non-invasive detection and staging of lung cancer.143 
While significant progress has been made for the diagnosis of intermediate and late stage lung 
cancer144 in the field of liquid biopsy and the use of markers of cancer that can be detected based 
on the analysis of blood borne analytes (e.g. circulating proteins145, autoantibodies146, circulating 
tumor cells (CTCs)147, circulating tumor microemboli (CTM)148, and CTC-derived nucleic acid 
signatures147) , these techniques have failed to detect NSCLC at early stage of development mainly 
due to their failure to detect molecular markers of NSCLC and particularly those of EMT 
associated with the onset of NSCLC.149 Although molecular-based diagnostics can, principally, 
help distinguish early stage lung cancer from benign nodules that are incidentally detected by a 
CT scan, the impact has been incremental reducing the number of false positives by 32%.150   
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3.2.2 Protease Activity and Cancer 
Extracellular proteases are associated with a variety of disease processes.110,136,151 In 
particular increased activity of matrix metalloproteinases136 and cathepsins110 have been reported 
for a variety of diseases and that makes them potential biomarker candidates. The activities of 
these enzymes, however, are regulated through a complex network of proteases91 and, therefore, 
their activities are highly context dependent. This hampers their potential use as clinical 
biomarkers of disease states. Following the pioneering research of Weissleder et al.108, 
molecular152, macromolecular153 and nanoparticle-based154 protease sensors have been reported 
for in-vivo imaging and in-vitro diagnostics of proteases and posttranslational modification 
enzymes (e.g. arginase80) that make use of fluorescence and magnetic principles.155 However, the 
limits of protease detection (LOD’s) of the state-of-the-art technology are sub-picomolar (sub-
ng/mg)108,152-155, which is sufficient for in-vivo imaging of tumors108,152-155, but not for the in-vitro 
detection of human cancers156 in their earliest stages. Competing technologies for quantitative 
protease detection, such as immunosorbent assays157, quantum dot barcode technology158, and 
immunobeads159 have similar LOD’s.  
 
 
Figure 33: Mechanistic scheme of the “light switch effect” upon proteolytic cleavage. The 
fluorophore is switched on due to the increase in distance between the Fe/Fe3O4 core/shell 
nanoparticle, leading to decreased Förster Resonance Energy Transfer (FRET), k1, and 
dipole-surface energy transfer (SET), k2.  
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 3.2.3 Fe/Fe3O4 core/shell Nanoparticle-based Nanobiosensors  
The Bossmann and Troyer groups have developed nanobiosensors for protease 
detection122,160 that are capable of detecting protease122 and arginase80 activities over a wide 
activity range down to sub-femtomolar LOD’s. These nanoplatforms consist of dopamine-covered, 
water-dispersible iron/iron oxide core/shell nanoparticles, to which one fluorescent dye (TCPP, 
tetrakis-carboxyphenyl porphyrin) is tethered via a protease-specific or highly selective consensus 
sequence.129 A second dye (Cyanine 5.5) is permanently linked to the dopamine coating. This 
design enables both, plasmon-resonance quenching (SET)161 and Förster Resonance Energy 
Transfer (FRET) quenching162 of the tethered TCPP units. Once TCPP is released via proteolytic 
cleavage of the consensus sequence, its fluorescence will increase. This “light switch effect”122 
enables highly sensitive detection of protease activity by quantitative fluorescence measurements. 
By using a mathematical model describing the quenching occurring between donor-acceptor pairs 
on a spherical surface130,163, we have determined that 35 TCPP and 50 cyanine 5.5 dyes result in 
optimal quenching at the surface of dopamine-coated Fe/Fe3O4 nanoparticles (Fe(0) core: d = 13 
± 0.5 nm, Fe3O4 shell: d = 2 ± 0.5 nm, dopamine: 1 ± 0.2 nm, surface: 1.13 x 10
-15 m2).  Therefore, 
for most proteases, a substantial fluorescence increase is observed when the consensus sequence 
between the nanoparticle and TCPP is cleaved. However, for uPA and MMP-9, a decrease in 
fluorescence intensity was detected. In an earlier report, we have discussed possible reasons for 
this anomaly. In short, the Fe/Fe3O4 core/shell nanoparticles feature a Fe plasmon that is distinctly 
weaker than an Au plasmon.122,164 The Fe-core is able to quench TCPP fluorescence very 
efficiently, if TCPP is sufficiently close. However, for the consensus sequences for uPA 
(GAGSGR-SAG) and MMP9 (GAGVPLS-LYSGAG) the distance between Fe/Fe3O4 and tethered 
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TCPP is optimal with regard to fluorescence enhancement (between 5 and 7 nm). Therefore, TCPP 
fluorescence is enhanced while TCPP is bound and it decreases after enzymatic cleavage.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Nanobiosensor for in-vitro protease detection. For each protease, a highly 
selective consensus sequence is employed as a tether between nanoparticle and TCPP 
(tetrakis-4-carboxyphenyl-porphyrin). Cyanine 5.5 is linked permanently to the Fe/Fe3O4 
nanoparticles. Cited from reference 122 with permission from the Beilstein Journal of 
Nanotechnology. 
 
In 2014, we have published detailed synthetic procedures of the Fe/Fe3O4-based 
nanobiosensors, as well as their calibration for 12 commercially available proteases.122 In 2016, 
we have reported the matrix effects of serum for the protease detection by the nanobiosensors.81 
We utilized this data for developing a liquid biopsy for the staging of breast cancer. It is noteworthy 
that recognition of breast cancer at stage 1 can be routinely achieved and that stage 0 detection of 
breast cancer is possible.  In this report, we would like to extend this methodology to the detection 
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of non-small-cell lung cancer. As noted earlier, this cancer is characterized by the rapid decrease 
of survival rates with increasing stage. Therefore, the opportunity to save lives by detecting cancer 
at the earliest possible stage during routine blood tests is even higher. Furthermore, the liquid 
biopsy developed here is, principally, also capable of detecting the recurrence of (lung) cancer 
earlier than any other known method. 
 
3.3 Serum Samples from the Southeastern Nebraska Cancer Center 
We have obtained serum samples that were stored at -80oC from 33 non-small-cell lung 
cancer patients (20 males, 13 females, ages 42 to 70 years; 9 stage I, 12 stage II, 12 stage III), as 
well as 20 healthy human subjects (10 males and 10 females, ages 36 to 80 years) from the 
Southeast Nebraska Cancer Center, Lincoln, NE.  Serum is especially suitable for liquid biopsies, 
because it retains its proteasome for 10h when frozen at -80oC. All patients were Caucasian. No 
significant statistical differences in the protease expression pattern between the females and males 
of the control group were found. 
 
 3.4 Selection of the Proteases of Interest 
Due to the fact that about two percent of the human genome encode for proteases, every 
selection of target proteases is somewhat arbitrary. Based on literature evidence95,111,165-167, we 
have selected the matrix metalloproteinases MMP 1, 2, 3, 7, 9, 13, uPA, the cathepsins CTS B and 
L. This panel of proteases has the additional advantage that the results can be directly compared 
with those from the breast cancer detection study reported earlier.81 We hypothesize that due to 
dysfunctional protease expression by tumor and stroma cells, the whole web of proteases is out of 
equilibrium in cancer. This leads to enhanced activity of some proteases and decreased activity of 
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other. By observing the activity of multiple proteases in a liquid biopsy “barcodes for tumor 
detection” can be established, which are either “up” or “down” compared to normal protease 
activities. This will enable the detection of both, the types and stages of numerous solid tumors. 
 
Table 7: Peptide Sequences for Nanobiosensors129 
The consensus sequences are written in single-letter code. 
Nanobiosensor Oligopeptide Used as Cleavable Tether 
MMP 1 GAGVPMS-MRGGAG 
MMP 2 GAGIPVS-LRSGAG 
MMP 3 GAGRPFS-MIMGAG 
MMP 7 GAGVPLS-LTMGAG 
MMP 9 GAGVPLS-LYSGAG 
MMP 13 GAGPQGLA-GQRGIVAG 
uPA GAGSGR-SAG 
Cathepsin B (CTS B) GAGSLLKSR-MVPNFNAG 
Cathepsin L (CTS L) GAGSGVVIA-TVIVITAG 
Consensus Sequences, Peptide Spacers 
 
 3.5 Methods 
 3.5.1 Synthesis, Characterization and Validation of the Nanobiosensors 
The synthesis and characterization of all components for the nanobiosensors and their final 
assembly and characterization is described in detail in reference 122 and in chapter 4. The effects 
of the serum matrix on the nanobiosensors are discussed in reference81, as well as cross-sensitivity 
of the nine proteases used for this study. 
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 3.5.2 Standard Procedure of Preparing Protease Assays (with thermally inactivated 
serum134) 
“3.0 mg of nanoplatform were dissolved in 3.0 mL of PBS. The dispersion was sonicated 
for 10 min. The resulting dispersion is chemically stable for 14 days at 4 °C. 900 mg of dextran 
was dissolved in 90.0 mL of PBS. Stock solutions of all 9 enzymes were prepared by consecutive 
dilution of commercially available proteases (Enzo Lifesciences). 3.0 mL of PBS–dextran (10 mg 
dextran in 1.0 mL of PBS) are mixed with 75 μL of the nanoplatform dispersion (3.0 mg in 3.0 
mL of PBS, see above) and 30 μL of each of the proteases at every concentration level in PBS. 
The dispersions were incubated at 25 °C for 60 min, followed by the recording of a fluorescence 
spectrum at 25 °C using a Fluoromax2 spectrometer (λem = 421 nm, λex = 620–680 nm)” (Quoted 
from reference 81 with permission from the Beilstein Journal of Nanotechnology.).  
 
 3.5.3 Standard Procedure of Preparing Protease Assays (with proteolytically active 
serum) 
Exactly the same procedure as describe above was followed, with the exception that 5 μL 
of serum were added instead of 30 μL of commercially available proteases in PBS.  
 
 3.6 Results and Discussion 
 3.6.1 Diagnosis of Non-Small-Cell Lung Cancer in Serum 
The activities of MMP-1,-2,-3,-7,-9,-13, uPA, and CTS -B and -L in the sera of 33 non-
small-cell lung cancer patients and 20 healthy volunteers were determined by following the 
procedures described in the section 3.5. Calibration curves obtained with commercially available 
proteases in heat-deactivated serum were used for determining the protease activities. All 
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Fe/Fe3O4- based nanobiosensors utilized possess (sub) femtomolar Limits of Detection (LOD) and 
an extensive, but non-linear range from 10-16 to 10-6 moles L-1 of protease activity. The results 
were statistically analyzed and displayed in a series of boxplots and bar graphs. Our conclusions 
are based on the data range that correlates with each cancer stage in comparison with the range of 
presumably healthy persons.119,168  
 The activities of Cathepsin-B in the apparently healthy control group and the groups at 
NSCLC stages 1, 2, and 3 are shown in Figure 35. A significant increase from state 1 to stage 2 is 
clearly discernible. This protease is suitable to detect when NSCLC cancer is becoming distant. 
This is in agreement with the literature, in which cathepsin B is established as a valuable prognostic 
factor for non-small-cell lung cancer.109 
 
Figure 35: Bar graph (left, showing means and standard deviations) and box plot (right, 
indicating the observed data range) for cathepsin B. The group sizes are H (apparently 
healthy control group, n = 20), 1: NSCLC cancer stage 1 (n = 9), 2: NSCLC cancer stage 2 (n 
= 12), 3: NSCLC cancer stage 3 (n = 12). All biospecimens were obtained from the 
Southeastern Nebraska Cancer Center (SNCC). Ip: fluorescence intensity of the measured 
protease, Is: fluorescence intensity of the solvent, Ic: fluorescence intensity of the 
nanobiosensor in the absence of the respective protease. 
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Contrary to cathepsin B, the activity of cathepsin L increases stepwise from the group of healthy 
volunteers to the patient group at stage 3 (Figure 36). One possible reason for the observed 
stepwise increase is that cathepsin L is involved in angiogenesis.111,169 The connection of tumors 
and metastases to blood supply has to increase steadily with tumor growth to fulfill the nutritional 
needs of the tumor and permit the required access to the body’s oxygen supply. Cathepsin L is a 
very suitable protease to monitor the general process of NSCLC cancer.  
 
Figure 36: Bar graph (left, showing means and standard deviations) and box plot (right, 
indicating the observed data range) for cathepsin L. The group sizes are H (apparently 
healthy control group, n = 20), 1: NSCLC cancer stage 1 (n = 9), 2: NSCLC cancer stage 2 (n 
= 12), 3: NSCLC cancer stage 3 (n = 12). All biospecimens were obtained from the 
Southeastern Nebraska Cancer Center (SNCC). Ip: fluorescence intensity of the measured 
protease, Is: fluorescence intensity of the solvent, Ic: fluorescence intensity of the 
nanobiosensor in the absence of the respective protease.   
 
Urokinase plasminogen activator (uPA) is, such as cathepsin B, a good indicator for non-
small-cell-lung cancer becoming distant (Figure 37). For the selection of a panel of proteases that 
permits the best “barcode detection”, cathepsin B and uPA are probably redundant. However, since 
the nanobiosensor for uPA is one of the two (to date) that decrease in fluorescence intensity upon 
enzymatic cleavage of the consensus sequence between dopamine-coated Fe/Fe3O4 nanoparticles 
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and TCPP, cathepsin B (which increases in fluorescence when cleaved) is better suited for 
detection purposes. Monitoring the increase of a fluorescence signal is a better approach than a 
decrease, which would also be caused by photobleaching of TCPP.170 
 
 
Figure 37: Bar graph (left, showing means and standard deviations) and box plot (right, 
indicating the observed data range) for uPA. The group sizes are H (apparently healthy 
control group, n = 20), 1: NSCLC cancer stage 1 (n = 9), 2: NSCLC cancer stage 2 (n = 12), 
3: NSCLC cancer stage 3 (n = 12). All biospecimens were obtained from the Southeastern 
Nebraska Cancer Center (SNCC). Ip: fluorescence intensity of the measured protease, Is: 
fluorescence intensity of the solvent, Ic: fluorescence intensity of the nanobiosensor in the 
absence of the respective protease.   
 
Matrix-metalloproteinase 1 (MMP-1) is an excellent enzyme for monitoring the occurrence 
(or recurrence) of non-small-cell lung cancer, because it is significantly elevated in stage 1, 
compared to the apparently healthy control group (Figure 38). Therefore, it is especially suited for 
very early detection of NSCLC.  
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Figure 38: Bar graph (left, showing means and standard deviations) and box plot (right, 
indicating the observed data range) for MMP-1. The group sizes are H (apparently healthy 
control group, n = 20), 1: NSCLC cancer stage 1 (n = 9), 2: NSCLC cancer stage 2 (n = 12), 
3: NSCLC cancer stage 3 (n = 12). All biospecimens were obtained from the Southeastern 
Nebraska Cancer Center (SNCC). Ip: fluorescence intensity of the measured protease, Is: 
fluorescence intensity of the solvent, Ic: fluorescence intensity of the nanobiosensor in the 
absence of the respective protease.   
 
 
Figure 39: Bar graph (left, showing means and standard deviations) and box plot (right, 
indicating the observed data range) for MMP-2. The group sizes are H (apparently healthy 
control group, n = 20), 1: NSCLC cancer stage 1 (n = 9), 2: NSCLC cancer stage 2 (n = 12), 
3: NSCLC cancer stage 3 (n = 12). All biospecimens were obtained from the Southeastern 
Nebraska Cancer Center (SNCC). Ip: fluorescence intensity of the measured protease, Is: 
fluorescence intensity of the solvent, Ic: fluorescence intensity of the nanobiosensor in the 
absence of the respective protease.   
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Contrary to MMP-1, which is a good marker for tissue alveolar remodeling processes115, 
the activity of MMP-2 increases again stepwise with increasing cancer stage of non-small-cell lung 
cancer (Figure 39). MMP-2 is associated in the literature with TMN stage, pathological 
differentiation and lymph node metastasis in NSCLC. 171 The steady increase in fluorescence 
signal and, at the same time, low signal-to-noise, makes MMP-2 a very suited biomarker for non-
small-cell lung cancer. 
MMP-3 is a similar biomarker as MMP-2, since it also shows a stepwise increase in 
nanobiosensor fluorescence as a function of non-small-cell lung cancer staging (Figure 40). MMP-
3 has been identified as a major player in matrix-metalloproteinase-induced lung fibrosis and other 
malignancies, among them lung cancer.172 MMP-3 has been recently proposed as a prognostic 
factor for poor survival in pancreatic, pulmonary, and mammary carcinoma.116 In this study, we 
were able to corroborate this finding while, at the same time, the sensitivity of detection of the 
nanobiosensors used is 100-1000 times for sensitive than conventionally used immunoassay 
technologies.  
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Figure 40: Bar graph (left, showing means and standard deviations) and box plot (right, 
indicating the observed data range) for MMP-3. The group sizes are H (apparently healthy 
control group, n = 20), 1: NSCLC cancer stage 1 (n = 9), 2: NSCLC cancer stage 2 (n = 12), 
3: NSCLC cancer stage 3 (n = 12). All biospecimens were obtained from the Southeastern 
Nebraska Cancer Center (SNCC). Ip: fluorescence intensity of the measured protease, Is: 
fluorescence intensity of the solvent, Ic: fluorescence intensity of the nanobiosensor in the 
absence of the respective protease.   
 
Contrary to the results obtained when detecting MMP-7 in the serum of breast cancer 
patients vs. healthy volunteers81, MMP-7 is statistically significant when diagnosing non-small-
cell lung cancer, albeit less significant than most other proteases (See Table 8). The fact that in 
NSCLC, MMP-7 slightly increases with increased cancer stage (Figure 41), but not in breast 
cancer, is an indication that the protease expression pattern of solid tumors differs according to 
tumor origin and stage. This can be explained by small differences in the biochemistry of the 
various cell types from which these solid tumors originate. These differences are partially retained 
in the developing tumors. However, major changes in protease expression occur during later 
stages.  
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Figure 41: Bar graph (left, showing means and standard deviations) and box plot (right, 
indicating the observed data range) for MMP-7. The group sizes are H (apparently healthy 
control group, n = 20), 1: NSCLC cancer stage 1 (n = 9), 2: NSCLC cancer stage 2 (n = 12), 
3: NSCLC cancer stage 3 (n = 12). All biospecimens were obtained from the Southeastern 
Nebraska Cancer Center (SNCC). Ip: fluorescence intensity of the measured protease, Is: 
fluorescence intensity of the solvent, Ic: fluorescence intensity of the nanobiosensor in the 
absence of the respective protease.   
 
As already discussed, the nanobiosensor for detecting MMP-9 in serum shows a decrease 
of TCPP fluorescence upon proteolytic cleavage (Figure 42). Therefore, the actual changes in 
fluorescence intensity as a factor of stage are small. However, since the experimental error is 
smaller than 2%, we can detect MMP-9 changes with very good accuracy. As shown in Table 8, 
MMP-9 is a viable biomarker for NSCLC. However, MMP-9 has been implicated in numerous 
inflammatory diseases, such as cardiovascular disorders, cancer, and even neuropsychiatric 
disorders.173 Therefore, it is not suited to be a “stand-alone biomarker”. However, it adds value to 
a panel of proteases for non-small-cell cancer detection, because this disease is inflammatory.  
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Figure 42: Bar graph (left, showing means and standard deviations) and box plot (right, 
indicating the observed data range) for MMP-9. The group sizes are H (apparently healthy 
control group, n = 20), 1: NSCLC cancer stage 1 (n = 9), 2: NSCLC cancer stage 2 (n = 12), 
3: NSCLC cancer stage 3 (n = 12). All biospecimens were obtained from the Southeastern 
Nebraska Cancer Center (SNCC). Ip: fluorescence intensity of the measured protease, Is: 
fluorescence intensity of the solvent, Ic: fluorescence intensity of the nanobiosensor in the 
absence of the respective protease.   
 
Together with MMP-1, -2, -3, -7. -11 (not tested here), MMP-13 (Collaginase-3) is 
implicated in inflammation-induced epithelial-to-mesenchymal transitions (EMT).117 However, 
MMP-13 does not correlate with NSCLC staging. One possible explanation for the observed 
behavior is that EMT occurs very early in the cancerogenesis.174 Therefore, significant changes in 
MMP-13 expression may occur before stage 1 is reached. 
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Figure 43: Bar graph (left, showing means and standard deviations) and box plot (right, 
indicating the observed data range) for MMP-13. The group sizes are H (apparently healthy 
control group, n = 20), 1: NSCLC cancer stage 1 (n = 9), 2: NSCLC cancer stage 2 (n = 12), 
3: NSCLC cancer stage 3 (n = 12). All biospecimens were obtained from the Southeastern 
Nebraska Cancer Center (SNCC). Ip: fluorescence intensity of the measured protease, Is: 
fluorescence intensity of the solvent, Ic: fluorescence intensity of the nanobiosensor in the 
absence of the respective protease.   
 
From the bar graphs, box plots and especially the significance table (Table 8), it is apparent 
that the signal quality of Cathepsin B and L, as well as MMP-1, -2 and -3 is superior to the signal 
quality of MMP-7 and -13. Highly significant differences are achieved with Cathepsin B and L, 
MMP- 1, -2 and -3.  
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Table 8: Significance Table: plot of the calculated p-values of each protease vs. cancer 
stage. 
Green: p-value significant (p < 0.05), nanobiosensor fluorescence in the disease group is higher 
than in the control group. Yellow: p-value significant (p < 0.05), nanobiosensor fluorescence in 
the disease group is lower than in the control group. Red: protease activity does not differ 
significantly in both, the cancer and the control groups.  
 
 
As summarized in the Significance Table (Table 8), Cathepsin-L and MMP-1, -2, -3, -7, 
and -9 are capable of detecting a statistically significant difference in nanobiosensor fluorescence 
between the group of patients with non-small-cell-lung cancer at stage 1 and the apparently healthy 
and age-matched control group. As already discussed in the introduction section, all patients were 
Caucasian. The nanobiosensors for eight proteases (Cathepsin-L, -B, uPA, MMP-1, -2, -3, -7 and 
-9) were able to differentiate between stage 2 and stage 3 NSCLC patients and the control group.  
The results presented in the Significance Table clearly indicate that the detection of stage 
I non-small-cell lung cancer and beyond is clearly possible by means of a liquid biopsy using either 
fresh serum or serum that has been stored for several years (up to five) at – 80oC. The Fe/Fe3O4 
core/shell nanoparticle-based nanobiosensors have been synthesized on the gram scale and can be 
stored (frozen) for up to four years under nitrogen/argon without losing activity. In aqueous 
buffers, they are stable for up to 7 days. Therefore, the technology that is described in this report 
is, principally, available for use in clinical laboratories. Conservatively estimated, the mortality of 
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non-small-cell lung cancer could be decreased by more than 30% if these tests would be routinely 
performed during yearly health check-ups.  
 
 3.7 Application of a Multivariate Model 
A combination of MMP 1 and Cathepsin B was chosen for the multivariate model. MMP-
1 achieves a good separation between the healthy group and stage 1, while Cathepsin B increases 
the separation between the later stages, a quality that MMP-1 lacks. The parameter’s values were 
linearized (log). This model’s coefficients are highly significant. The R2-value reaches 0.91. The 
cubic graph (Figure 44) shows how the data groupings shift to the right (MMP-1 influence) and 
back (Cathepsin B influence) with increasing cancer stages. This permits the precise detection of 
stage 1 NSC lung cancer by looking at only two variables. This approach can be, principally, 
enhanced by including more than two proteases.   
 
Figure 44: Multivariate Model: Cancer State over MMP-1 (1y) and Cathepsin-B (y) 
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Table 9: Multivariate Model: Cancer State over MMP-1 (1y) and Cathepsin-B (y) readings: 
Coefficients: 
 
Estimate Standard 
Error 
t-value Pr(>|t|)     
z-axis Intercept -0.52849 0.05615 -9.413 1.18x10-12 
MMP1 slope        0.90623 0.09336 9.707 4.34x10-13 
Cathepsin B slope       1.13514 0.10446 10.867 9.11x10-15 
     
Signif. codes:   0’***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘’  1 
Residual standard error: 0.1686 on 50 degrees of freedom 
Multiple R-squared:  0.9181, Adjusted R-squared:  0.9148  
F-statistic: 280.1 on 2 and 50 DF,  p-value: < 2.2x 10-16 
 
 3.8 Summary 
Non-small-cell lung cancer (NSCLC) can be reliably detected in a liquid biopsy measuring 
the protease activity of eight proteases (Cathepsin B, L, MMP-1, -2, -3, -7, -9), and uPA) utilizing 
Fluoromax2 spectrometer (λem = 421 nm, λex = 620–680 nm). MMP-13 proved to be an unreliable 
marker. Based on the fluorescence readings obtained from the groups of NSCLC patients and 
healthy volunteers (Figures 35-43), we have calculated the average protease concentrations for 
each NSCLC-stage and the age-matched control group. The results are summarized in Figure 45. 
From the real protease activities, not the integrated nanobiosensor fluorescence signals, it can be 
discerned that MMP-1 and MMP-9 exhibit the highest activities in the serum of non-small-cell 
lung cancer patients. It is reasonably well established that the activities of numerous proteases in 
cancer tissue and stroma correlate with their activities in blood, because virtually all proteases are 
involved in angiogenesis and ECM (extracellular matrix) degradation.121  Beginning with from 
stage 1, virtually all solid tumors are well connected to the blood supply. MMP-1 activity is related 
to tissue remodeling processes in the lung115, whereas MMP-9 is an inflammation marker, which 
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is involved in numerous processes in the human body and is not necessarily related to a disease.173 
This may explain the relatively high average activity of MMP-9 (8.60 x 10-13 M) in the apparently 
healthy control group. 
 
Figure 45: Average protease activity as a function of NSCL cancer stage/healthy control 
group for all nine proteases monitored in this study. 
The calibration curves reported in reference 81 were used for calculating the protease activities 
measured in serum. Note that the activity is shown on a logarithmic scale (log10 (protease activity)). 
The data summarized in this figure is also reported in Chapter 4, Section 4.4. 
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Chapter 4 - Experimental Section and Additional Procedures 
 4.1 Determination of Matrix Effects on the Observed Fluorescence Intensities 
of the Nanoplatforms 
 
 
 
 
Figure 46: “Matrix effects for MMP7, MMP13, and cathepsin L after 60 min of incubation 
at 25 oC under standard conditions (Taken with permission of Reference81) 
Ip: fluorescence signal after 60 min. of incubation; Ic: fluorescence signal in the absence of protease 
after 60 min. incubation; Is: fluorescence signal of serum/PBS-dextran alone. Experimental errors 
are indicated.”81  
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Figure 47: “Matrix effects for MMP1, MMP 2, MMP 3, and cathepsin B after 60 min of 
incubation at 25 oC under standard conditions (Taken with permission of Reference81) 
Triangles: fluorescence readings in PBS; Squares: fluorescence readings in PBS containing 
inactivated serum. Ip: fluorescence signal after 60 min. of incubation; Ic: fluorescence signal in the 
absence of protease after 60 min. incubation; Is: fluorescence signal of serum/PBS-dextran alone. 
Experimental errors are indicated.”81  
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Figure 48: “Matrix effects for MMP9 and uPA after 60 min of incubation at 25 oC under 
standard conditions (Taken with permission of Reference81) 
Triangles: fluorescence readings in PBS; Squares: fluorescence readings in PBS containing 
inactivated serum. Ip: fluorescence signal after 60 min. of incubation; Ic: fluorescence signal in the 
absence of protease after 60 min. incubation; Is: fluorescence signal of serum/PBS-dextran alone. 
Experimental errors are indicated.”81   
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Figure 49: “TEM (1a,1b) and HRTEM (1c) images of Fe/Fe3O4-core/shell nanoparticles 
that are forming the inorganic core of the nanoplatforms for protease detection, HRTEM 
images revealed that the Fe(0) centers are mostly crystalline (BCC).”122 (Taken with 
permission of the Royal Society of Chemistry122) 
 
 
 
 
Figure 50: “Light-Switch Effect” of the Fe/Fe3O4-nanoplatform for detecting MMP-13: 
fluorescence increase as a function of reaction time under standard conditions at 25 oC 
after addition of 1.0 x 10−12 mol L−1 of MMP-13; I: fluorescence intensity (Taken with 
permission from Royal Society of Chemistry122) 
 
 
88 
 4.2 Relative Error from 10 Independently Performed Protease Measurements 
 
 
Figure 51: 10 independent repetitions of measuring the activity of the Fe/Fe3O4-
nanoplatform for detecting MMP-13 under standard conditions at 25 oC after addition of 1.0 
x 10−13 mol L−1 of MMP13. The relative error was determined to be 2 percent. I: 
fluorescence intensity 
 
 4.3 Cross-Sensitivity of the Nanobiosensors 
“In order to determine the cross-sensitivities of the nanoplatforms, the following control 
experiments were conducted: The nanoplatforms for MMP 1, 2, 3, 7, 9, 13, uPA, and CTS B, L 
were (separately) incubated with 1.0 x 10−10 mol l−1 of MMP 1 under standard conditions. After 
60 min. of incubation at 25 oC, the fluorescence spectra of all nanoplatforms were recorded. The 
next set of experiments consisted of incubating the nanoplatforms for MMP 1, 2, 3, 7, 9, 13, uPA, 
and CTS B, L with 1.0 x 10−10 mol l−1 of MMP 2 under standard conditions. This is followed by 
MMP 3, 7, 9, 19, uPA and CTS B, and L. In Figure 52, the normalized results for this set of 
experiments are summarized. The normalization procedure consists of dividing each set of 
integrated fluorescence data for each enzyme by the fluorescence recording for the correct match 
in the entire set of nine nanoplatforms.  
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Set 1: integrated fluorescence recordings for all nine nanoplatforms incubated with MMP-1 (1.0 x 
10−10 mol l−1), divided by the integrated fluorescence signal obtained with the nanoplatform for 
MMP-1 in the presence of MMP-1; 
Set 2: integrated fluorescence recordings for all nine nanoplatforms incubated with MMP-2 (1.0 x 
10−10 mol l−1), divided by the integrated fluorescence signal obtained with the nanoplatform for 
MMP-2 in the presence of MMP-2 
Sets 3 to 8 have been recorded accordingly for MMP-3, -7, -9, -13, uPA and CTS B. 
Set 9: integrated fluorescence recordings for all nine nanoplatforms incubated with CTS L (1.0 x 
10−10 mol l−1), divided by the integrated fluorescence signal obtained with the nanoplatform for 
CTS L in the presence of CTS L.”122 (Taken with permission from Beilstein Journal of 
Nanotechnology).  
 
 
 
Figure 52: “Cross-sensitivities of the nanobiosensors used in this study. Further 
explanations are provided above.”81 (Taken with permission of Reference81) 
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 4.4 Means, Standard Deviations, and Average Protease Activities for Each 
Protease and Stage 
Table 10: Means, Standard Deviations, and Average Protease Activities in Serum for 
Cathepsin B (CTS B) 
Stages     Means    SD Average Protease Activity in Serum (mol L-1) 
H 1.360853   0.07226045 2.4 x 10-16 
1 1.356708 0.0532257 2.2 x 10-16 
2 2.312725 0.1794251 1.2 x 10-13 
3 2.417865 0.2105544 3.5 x 10-13 
 
 
Table 11: Means, Standard Deviations, and Average Protease Activities in Serum for 
Cathepsin L (CTS L) 
Stages     Means    SD Average Protease Activity in Serum (mol L-1) 
H 1.923536     0.40659660 1.8 x 10-15 
1 2.525293 0.0836583 2.5 x 10-15 
2 2.873535 0.2741506 1.4 x 10-13 
3 3.049788 0.3474912 1.2 x 10-12 
 
 
Table 12: Means, Standard Deviations, and Average Protease Activities in Serum for 
urokinase-type Plasminogen Activator (uPA) 
Stages     Means    SD Average Protease Activity in Serum (mol L-1) 
H 0.9848335       0.025264087 1.3 x 10-15 
1 0.9921240 0.023313962 1.2 x 10-15 
2 0.8921566 0.034226941 2.8 x 10-11 
3 0.8868113 0.021102354 7.4 x 10-11 
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Table 13: Means, Standard Deviations, and Average Protease Activities in Serum for 
Matrix Metalloproteinase 1 (MMP-1) 
Stages     Means    SD Average Protease Activity in Serum (mol L-1) 
H 1.314616     0.23507424 1.6 x 10-15 
1 2.4499240 0.13775162 8.3 x 10-8 
2 2.3424636 0.21967214 3.1 x 10-9 
3 2.3840819 0.11741315 4.5 x 10-9 
 
 
Table 14: Means, Standard Deviations, and Average Protease Activities in Serum for 
Matrix Metalloproteinase 2 (MMP-2) 
Stages     Means    SD Average Protease Activity in Serum (mol L-1) 
H 1.551050     0.2210302 4.0 x 10-15 
1 1.778842 0.1615579 7.0 x 10-13 
2 1.797345 0.2712342 8.8 x 10-13 
3 1.917671 0.1823691 9.1 x 10-13 
 
 
Table 15: Means, Standard Deviations, and Average Protease Activities in Serum for 
Matrix Metalloproteinase 3 (MMP-3) 
Stages     Means    SD Average Protease Activity in Serum (mol L-1) 
H 1.276774        0.10293781 3.4 x 10-16 
1 1.387032 0.05586801 8.2 x 10-15 
2 1.670378 0.13738547 1.2 x 10-14 
3 1.789161 0.19236757 9.3 x 10-14 
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Table 16: Means, Standard Deviations, and Average Protease Activities in Serum for 
Matrix Metalloproteinase 7 (MMP-7) 
Stages     Means    SD Average Protease Activity in Serum (mol L-1) 
H 1.265858     0.08413963 6.4 x 10-16 
1 1.353391 0.05112853 9.2 x 10-16 
2 1.352708 0.09032285 9.1 x 10-15 
3 1.365533 0.11891228 9.5 x 10-15 
 
 
Table 17: Means, Standard Deviations, and Average Protease Activities in Serum for 
Matrix Metalloproteinase 9 (MMP-9) 
Stages     Means    SD Average Protease Activity in Serum (mol L-1) 
H 0.9622952     0.011980785 8.6 x 10-13 
1 0.94443 0.012026643 1.3 x 10-10 
2 0.941885 0.011387601 1.4 x 10-10 
3 0.940606 0.010589256 2.6 x 10-10 
 
 
Table 18: Means, Standard Deviations, and Average Protease Activities in Serum for 
Matrix Metalloproteinase 13 (MMP-13) 
Stages     Means    SD Average Protease Activity in Serum (mol L-1) 
H 2.402871     0.6767673 3.2 x 10-15 
1 2.426960 0.5062057 7.7 x 10-15 
2 2.443162 0.5665877 7.8 x 10-15 
3 2.690081 1.1047931 9.7 x 10-15 
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Appendix A - Data tables 
Table 19: Fluorescence intensity data and p-values for Arginase in Fig 24 
Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
Sample ID patient Sample ID Patient Sample ID patient Sample ID Patient 
2720 308.7778 5327 102.2222 2689 290.5556 851 106.4444 
4236 249.7778 5247 156.8889 2996 344.6667 7428 103.0000 
4967 114.2222 7433 110.2222 3824 151.5556     
7253 158.6667 9829 126.1111 5273 139.3333     
8306 123.1111 10550 107.3333 5237 107.6667     
9620 148.8889     5417 111.1111     
9928 130.2222     6839 127.1111     
        7779 144.0000     
        8417 98.2222     
Sample ID control Sample ID Control Sample ID control Sample ID Control 
17424 109.7778 21486 141.4444 2741 206.5556 5783 126.4444 
17297 122.4444 17370 118.6667 17170 129.5556 17125 121.3333 
9178 115.5556 17268 116.8889 3371 101.8889     
4650 122.2222 20834 130.4444 3319 113.3333     
8170 114.3333 17468 122.0000 3754 93.7778     
6194 113.1111     9503 111.3333     
20483 109.2222     8441 116.2222     
        4185 107.7778     
        17180 126.2222     
 
Table 20: Mean values and standard deviations of fluorescence intensities in Table 10 
  Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
  Control Patient Control Patient Control  Patient Control  Patient 
mean 115.2381 176.2381 125.8889 120.5556 122.9630 168.2469 123.8889 104.7222 
SD 5.3566 73.9566 10.1367 22.1850 33.2447 87.5471 3.6141 2.4356 
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Table 21: Fluorescence intensity data and p-values for Cathepsin B in Fig 25 
Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
Sample ID patient Sample ID Patient Sample ID patient Sample ID Patient 
2720 3638.7778 5327 3283.6667 2689 2804.6667 851 3567.3333 
4236 3091.0000 5247 3794.0000 2996 1235.2222 7428 2976.5556 
4967 2731.5556 7433 3630.5556 3824 3799.0000     
7253 3220.0000 9829 3585.7778 5273 3424.5556     
8306 3396.4444 10550 3916.1111 5237 3003.3333     
9620 3686.2222     5417 2319.1111     
9928 3086.2222     6839 3235.0000     
        7779 3677.2222     
        8417 2913.0000     
Sample ID control Sample ID Control Sample ID control Sample ID Control 
17424 3954.3333 21486 3579.1111 2741 4300.5556 5783 3503.3333 
17297 4264.6667 17370 2581.0000 17170 4208.5556 17125 3708.5556 
9178 2573.6667 17268 3355.4444 3371 2717.3333     
4650 3626.6667 20834 3970.7778 3319 3191.6667     
8170 3555.2222 17468 3697.6667 3754 3170.5556     
6194 3405.7778     9503 3321.4444     
20483 4083.5556     8441 3506.7778     
        4185 4039.6667     
        17180 3614.1111     
 
Table 22: Mean values and standard deviations of fluorescence intensities in Table 11 
  Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
  Control Patient Control Patient Control  Patient Control  Patient 
mean 3637.6984 3264.3175 3436.8000 3642.0222 3563.4074 2934.5679 3605.9444 3271.9444 
   SD 560.5072 337.4507 527.3634 239.7580 531.4033 784.0405 145.1140 417.7430 
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Table 23: Fluorescence intensity data and p-values for Cathepsin D in Fig 26 
Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
Sample ID patient Sample ID Patient Sample ID patient Sample ID patient 
2720 317.4444 5327 360.8889 2689 305.7778 851 248.2222 
4236 196.0000 5247 397.6667 2996 257.7778 7428 234.0000 
4967 282.8889 7433 283.4444 3824 328.6667     
7253 258.8889 9829 269.1111 5273 281.2222     
8306 266.6667 10550 253.8889 5237 223.2222     
9620 296.4444     5417 250.5556     
9928 316.2222     6839 254.4444     
        7779 315.5556     
        8417 202.6667     
Sample ID control Sample ID Control Sample ID control Sample ID Control 
17424 264.7778 21486 291.7778 2741 315.0000 5783 281.7778 
17297 270.0000 17370 273.3333 17170 298.3333 17125 240.0000 
9178 239.3333 17268 270.6667 3371 219.4444     
4650 259.8889 20834 286.1111 3319 299.0000     
8170 264.8889 17468 253.1111 3754 224.5556     
6194 212.7778     9503 250.1111     
20483 282.2222     8441 253.6667     
        4185 242.3333     
        17180 260.4444     
 
Table 24: Mean values and standard deviations of fluorescence intensities in Table 14 
  Ductal Adenocarcinoma Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
  Control Patient Control Patient Control  Patient Control  Patient 
mean 256.2698 276.3651 275.0000 313.0000 262.5432 268.8765 260.8889 241.1111 
SD 23.0948 41.9918 15.0468 62.7608 34.1110 42.4310 29.5413 10.0566 
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Table 25: Fluorescence intensity data and p-values for Cathepsin E in Fig 27 
Ductal Adenocarcinoma Neuroendocrine Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
Sample ID patient Sample ID patient Sample ID patient 
Sample 
ID 
patient 
2720 12948.2222 5327 11465.1111 2689 11646.1111 851 10322.4444 
4236 7478.5556 5247 14530.3333 2996 2637.7778 7428 10493.1111 
4967 10721.7778 7433 8826.6667 3824 8623.0000     
7253 10101.2222 9829 11112.3333 5273 9005.4444     
8306 10857.8889 10550 11283.6667 5237 8618.0000     
9620 9654.3333     5417 5787.0000     
9928 5719.2222     6839 11375.0000     
        7779 8508.0000     
        8417 8964.1111     
Sample ID control Sample ID control Sample ID control 
Sample 
ID Control 
17424 10449.3333 21486 12870.0000 2741 10783.7778 5783 12284.8889 
17297 10298.3333 17370 10947.6667 17170 11149.6667 17125 11509.1111 
9178 10247.4444 17268 10526.5556 3371 9004.2222     
4650 9936.2222 20834 10784.7778 3319 11528.4444     
8170 12849.7778 17468 9984.0000 3754 10559.2222     
6194 10483.1111     9503 10829.1111     
20483 10118.6667     8441 10719.6667     
        4185 12375.5556     
        17180 14465.7778     
 
Table 26: Mean values and standard deviations of fluorescence intensities in Table 16 
  Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
  Control Patient Control Patient Control  Patient Control  Patient 
mean 10626.1 9640.17 11022.60 11443.62 11268.3827 8351.6049 11897.0000 10407.7778 
SD 998.387 2375.39 1095.4236 2031.750 1495.3726 2742.9787 548.5577 120.6796 
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Table 27: Fluorescence intensity data and p-values for UpA in Fig 28 
Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
Sample ID patient Sample ID patient Sample ID patient Sample ID patient 
2720 159.0000 5327 107.8889 2689 193.3333 851 130.1111 
4236 143.8889 5247 117.7778 2996 353.6667 7428 91.1111 
4967 114.1111 7433 93.0000 3824 100.7778     
7253 111.2222 9829 152.8889 5273 164.1111     
8306 109.3333 10550 107.5556 5237 148.6667     
9620 130.6667     5417 106.3333     
9928 152.0000     6839 111.1111     
        7779 121.8889     
        8417 219.2222     
Sample ID control Sample ID control Sample ID control Sample ID control 
17424 110.8889 21486 104.1111 2741 118.0000 5783 108.1111 
17297 108.0000 17370 77.6667 17170 102.6667 17125 104.1111 
9178 87.5556 17268 108.5556 3371 97.0000     
4650 102.4444 20834 138.3333 3319 104.7778     
8170 110.8889 17468 100.0000 3754 98.8889     
6194 118.2222     9503 99.4444     
20483 117.4444     8441 118.5556     
        4185 112.8889     
        17180 129.6667     
 
Table 28: Mean values and standard deviations of fluorescence intensities in Table 18 
  Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
  Control Patient Control Patient Control  Patient Control  Patient 
mean 107.9206 131.4603 105.7333 115.8222 109.0988 168.7901 106.1111 110.6111 
SD 10.4816 20.5572 21.7599 22.5272 11.2358 80.4713 2.8284 27.5772 
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Table 29: Fluorescence intensity data and p-values for MMP-1 in Fig 29 
Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
Sample ID patient Sample ID patient Sample ID patient Sample ID patient 
2720 647.7778 5327 431.2222 2689 611.6667 851 583.4444 
4236 592.1111 5247 328.6667 2996 494.6667 7428 293.0000 
4967 483.3333 7433 291.2222 3824 471.0000     
7253 326.7778 9829 321.7778 5273 607.2222     
8306 312.3333 10550 231.8889 5237 533.2222     
9620 297.5556     5417 325.5556     
9928 323.4444     6839 305.0000     
        7779 252.7778     
        8417 239.4444     
Sample ID control Sample ID control Sample ID control Sample ID control 
17424 492.0000 21486 337.5556 2741 495.3333 5783 348.7778 
17297 540.7778 17370 264.4444 17170 511.5556 17125 223.6667 
9178 222.3333 17268 249.1111 3371 422.0000     
4650 384.7778 20834 269.2222 3319 339.0000     
8170 223.5556 17468 280.7778 3754 230.5556     
6194 241.4444     9503 412.6667     
20483 292.3333     8441 189.8889     
        4185 181.8889     
        17180 207.1111     
 
Table 30: Mean values and standard deviations of fluorescence intensities in Table 20 
  Ductal 
Adenocarcinoma 
Neuroendocrine Tumor Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
  Control Patient Control Patient Control  Patient Control  Patient 
mean 342.4603 426.1905 280.2222 320.9556 332.2222 426.7284 286.2222 438.2222 
SD 132.1416 147.1088 34.0046 72.5186 133.3186 147.9377 88.4669 205.3752 
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Table 31: Fluorescence intensity data and p-values for MMP-3 in Fig 30 
Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
Sample ID patient Sample ID patient Sample ID patient Sample ID patient 
2720 94.8889 5327 60.1111 2689 89.8889 851 73.3333 
4236 85.6667 5247 74.1111 2996 307.3333 7428 66.2222 
4967 64.4444 7433 59.4444 3824 66.7778     
7253 70.6667 9829 63.1111 5273 80.8889     
8306 78.0000 10550 49.0000 5237 82.1111     
9620 85.7778     5417 66.6667     
9928 100.1111     6839 68.5556     
        7779 68.5556     
        8417 76.3333     
Sample ID control Sample ID control Sample ID control Sample ID control 
17424 77.6667 21486 63.7778 2741 64.3333 5783 70.3333 
17297 76.1111 17370 53.2222 17170 75.2222 17125 53.5556 
9178 53.5556 17268 47.8889 3371 70.5556     
4650 73.2222 20834 60.4444 3319 68.8889     
8170 62.5556 17468 48.8889 3754 59.8889     
6194 53.7778     9503 66.5556     
20483 45.3333     8441 56.8889     
        4185 48.6667     
        17180 59.2222     
 
Table 32: Mean values and standard deviations of fluorescence intensities in Table 22 
  Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
  Control Patient Control Patient Control  Patient Control  Patient 
mean 63.1746 82.7937 54.8444 61.1556 63.3580 100.7901 61.9444 69.7778 
SD 12.7662 12.7154 7.0293 8.9923 8.0712 77.8792 11.8637 5.0283 
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Table 33: Fluorescence intensity data and p-values for MMP-9 in Fig 31 
Ductal 
Adenocarcinoma 
Neuroendocrine Tumor Metastatic Adenocarcinoma 
Metastatic 
Neuroendocrine 
Sample ID patient Sample ID patient Sample ID patient Sample ID patient 
2720 174.1111 5247 229.6667 2689 271.1111 851 174.7778 
4236 246.5556 7433 157.0000 2996 322.4444 7428 156.0000 
4967 167.7778 9829 151.7778 3824 185.6667     
7253 180.7778 10550 192.2222 5273 178.0000     
8306 193.2222     5237 178.5556     
9620 205.7778     5417 137.1111     
9928 176.4444     6839 159.0000     
        7779 192.7778     
        8417 156.8889     
Sample ID control Sample ID control Sample ID control Sample ID control 
17424 151.3333 21486 192.3333 2741 179.8889 5783 182.7778 
17297 203.1111 17370 152.1111 17170 185.6667 17125 202.7778 
9178 152.8889 17268 205.2222 3371 140.2222     
4650 159.0000 20834 183.8889 3319 179.7778     
8170 183.4444 17468 181.6667 3754 171.3333     
6194 176.5556     9503 164.3333     
20483 168.4444     8441 179.1111     
        4185 193.7778     
        17180 210.1111     
 
Table 34: Mean values and standard deviations of fluorescence intensities in Table 24 
  Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
  Control Patient Control Patient Control  Patient Control  Patient 
mean 170.6825 192.0952 183.0444 183.6667 178.2469 197.9506 192.7778 165.3889 
SD 18.6256 27.2097 19.6062 36.1165 19.3799 59.9038 14.1421 13.2779 
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Table 35: Fluorescence intensity data and p-values for Neutrophil Elastase in Fig 32 
Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
Sample ID patient Sample ID patient Sample ID patient Sample ID patient 
2720 3973.5556 5327 1767.2222 2689 3517.2222 851 2163.1111 
4236 3367.7778 5247 2012.5556 2996 1038.7778 7428 1477.5556 
4967 1811.1111 7433 1453.0000 3824 2700.5556     
7253 1661.4444 9829 1650.0000 5273 1841.3333     
8306 1664.6667 10550 1601.7778 5237 1978.6667     
9620 1456.7778     5417 1138.1111     
9928 1172.0000     6839 1491.1111     
        7779 1433.3333     
        8417 1655.2222     
Sample ID control Sample ID control Sample ID control Sample ID control 
17424 2889.1111 21486 1794.6667 2741 2675.3333 5783 1638.4444 
17297 1954.2222 17370 1329.4444 17170 2004.1111 17125 1778.8889 
9178 1350.0000 17268 1694.8889 3371 1587.4444     
4650 1559.2222 20834 1436.6667 3319 1571.3333     
8170 1982.7778 17468 1506.1111 3754 1636.7778     
6194 1548.2222     9503 1496.4444     
20483 1497.2222     8441 1691.0000     
        4185 1699.4444     
        17180 2033.5556     
 
Table 36: Mean values and standard deviations of fluorescence intensities in Table 26 
  Ductal 
Adenocarcinoma 
Neuroendocrine 
Tumor 
Metastatic 
Adenocarcinoma 
Metastatic 
Neuroendocrine 
  Control Patient Control Patient Control  Patient Control  Patient 
mean 1825.8254 2158.1905 1552.3556 1696.911 1821.7160 1866.037 1708.6667 1820.3333 
SD 525.0757 1067.2386 189.8962 209.3554 370.2063 792.3547 99.3092 484.7610 
 
 
 
 
 
 
